SARS-CoV-2 replication and drug discovery
Farah Nazir, Arnaud John Kombe Kombe, Zunera Khalid, Shaheen Bibi, Hongliang Zhang, Songquan Wu, Tengchuan Jin
Molecular and Cellular Probes, doi:10.1016/j.mcp.2024.101973
Protease inhibitor 3C-like protease (3CL pro ) Main protease (M
Ethics approval and consent to participate Not applicable.
Competing interests The authors declare no conflicts of interest relevant to this article.
Consent for publication Not applicable.
References
Abel, Takahashi, Peer, Redon, Nichols et al., Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial, Clin. Cancer Res,
doi:10.1158/1078-0432.CCR-23-0536Agostini, Andres, Sims, Graham, Sheahan et al., Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease, in eng, mBio,
doi:10.1128/mBio.00221-18Ahmed, Sharma, Al-Ghamdi, Al-Yami, Al-Salami et al., A comprehensive analysis of cis-acting RNA elements in the SARS-CoV-2 genome by a bioinformatics approach, Front. Genet,
doi:10.3389/fgene.2020.572702Albulescu, Van Hoolwerff, Wolters, Bottaro, Nastruzzi et al., Suramin inhibits chikungunya virus replication through multiple mechanisms, Antiviral Res,
doi:10.1016/j.antiviral.2015.06.013Alugubelli, Geng, Yang, Shaabani, Khatua et al., A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals, Eur. J. Med. Chem,
doi:10.1016/j.ejmech.2022.114596Ambike, Cheng, Feuerherd, Velkov, Baldassi et al., Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread, Nucleic Acids Res,
doi:10.1093/nar/gkab1248Amin, Banerjee, Gayen, Jha, Protease targeted COVID-19 drug discovery: what we have learned from the past SARS-CoV inhibitors?, Eur. J. Med. Chem,
doi:10.1016/j.ejmech.2021.113294Amin, Banerjee, Ghosh, Gayen, Jha, Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors, Bioorg. Med. Chem,
doi:10.1016/j.bmc.2020.115860Amporndanai, Meng, Shang, Jin, Rogers et al., Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives, Nat. Commun,
doi:10.1038/s41467-021-23313-7Ashburn, Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov,
doi:10.1038/nrd1468Bai, Cao, Liu, Li, The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation, Viruses
Bakovic, Risner, Bhalla, Alem, Chang et al., Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture, Viruses,
doi:10.3390/v13020271Baldassi, Ambike, Feuerherd, Cheng, Peeler et al., Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes, J Control Release,
doi:10.1016/j.jconrel.2022.03.051Bassett, Salemi, Magalis, Lessons learned and yet-to-Be learned on the importance of RNA structure in SARS-CoV-2 replication, Microbiol. Mol. Biol. Rev,
doi:10.1128/mmbr.00057-21Batool, Vuthaluru, Hassan, Bseiso, Tehseen et al., Efficacy and safety of favipiravir in treating COVID-19 patients: a meta-analysis of randomized control trials, Cureus,
doi:10.7759/cureus.33676Benvenuto, Angeletti, Giovanetti, Bianchi, Pascarella et al., Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy, J. Infect,
doi:10.1016/j.jinf.2020.03.058Bernal, Gomes Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of covid-19 in nonhospitalized patients, N. Engl. J. Med,
doi:10.1056/NEJMoa2116044Bessa, Guseva, Camacho-Zarco, Salvi, Maurin et al., The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex with its viral partner nsp3a, Sci. Adv
Bhatt, Scaiola, Loughran, Leibundgut, Kratzel et al., Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome, Science,
doi:10.1126/science.abf3546Boras, Jones, Anson, Arenson, Aschenbrenner et al., .) have a sponsored research agreement with Pfizer to test compounds for inhibition of coronavirus proteases. The Frieman Laboratory, Nat. Commun,
doi:10.1038/s41467-021-26239-2Boras, Jones, Anson, Arenson, Aschenbrenner et al., Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19, bioRxiv,
doi:10.1101/2020.09.12.293498Brant, Tian, Majerciak, Yang, Zheng, SARS-CoV-2: from its discovery to genome structure, transcription, and replication, Cell Biosci,
doi:10.1186/s13578-021-00643-zBrennan, Nadella, Zhao, Dima, Jordan-Martin et al., Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial, Gut,
doi:10.1136/gutjnl-2022-326952Butt, Kanwal, Boceprevir and telaprevir in the management of hepatitis C virus-infected patients, Clin. Infect. Dis
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavirritonavir in adults hospitalized with severe covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2001282Chakraborty, Sharma, Bhattacharya, Agoramoorthy, Lee, The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies, Front. Pharmacol,
doi:10.3389/fphar.2021.704205Chatzianastasis, Nikolentzos, Vazirgiannis, Mass enhanced node embeddings for drug repurposing
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet,
doi:10.1016/S0140-6736(20)30211-7Chiara, D'erchia, Gissi, Manzari, Parisi et al., Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities, Brief Bioinform,
doi:10.1093/bib/bbaa297Cho, Kim, Chae, Meyer, Kim et al., In vitro metabolic characterization of the SARS-CoV-2 papain-like protease inhibitors GRL0617 and HY-17542, Front. Pharmacol,
doi:10.3389/fphar.2023.1067408Choy, Wong, Kaewpreedee, Sia, Chen et al., Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antiviral Res,
doi:10.1016/j.antiviral.2020.104786Cornillez-Ty, Liao, Yates 3rd, Kuhn, Buchmeier, Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling, J. Virol,
doi:10.1128/JVI.00842-09Cortese, Lee, Cerikan, Neufeldt, Oorschot et al., Integrative imaging reveals SARS-CoV-2-induced reshaping of subcellular morphologies, Cell Host Microbe,
doi:10.1016/j.chom.2020.11.003Crippa, Pacheco, Zuardi, Guimaraes, Campos et al., Cannabidiol for COVID-19 patients with mild to moderate symptoms (candidate study): a randomized, double-blind, placebo-controlled clinical trial, Cannabis Cannabinoid Res,
doi:10.1089/can.2021.0093Dampalla, Zheng, Perera, Wong, Meyerholz et al., Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2101555118Deftereos, Andronis, Friedla, Persidis, Persidis, Drug repurposing and adverse event prediction using high-throughput literature analysis, Wiley Interdiscip Rev Syst Biol Med,
doi:10.1002/wsbm.147Doijen, Temmerman, Van Den Eynde, Diels, Van Den Broeck et al., Identification of Z-tyr-ala-CHN(2), a cathepsin L inhibitor with broadspectrum cell-specific activity against coronaviruses, including SARS-CoV-2, in eng, Microorganisms,
doi:10.3390/microorganisms11030717Du, He, Zhou, Liu, Zheng et al., The spike protein of SARS-CoVa target for vaccine and therapeutic development, Nat. Rev. Microbiol,
doi:10.1038/nrmicro2090Fillmore, Bell, Shen, Nguyen, La et al., Disulfiram use is associated with lower risk of COVID-19: a retrospective cohort study, PLoS One,
doi:10.1371/journal.pone.0259061Freitas, Durie, Murray, Longo, Miller et al., Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease, ACS Infect. Dis,
doi:10.1021/acsinfecdis.0c00168Froggatt, Heaton, Heaton, Development of a fluorescence-based, high-throughput SARS-CoV-2 3CL(pro) reporter assay, J. Virol,
doi:10.1128/JVI.01265-20Fu, Huang, Tang, Liu, Liu et al., The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery, Nat. Commun,
doi:10.1038/s41467-020-20718-8Fu, Wang, Zheng, Yi, Li et al., SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response, Cell. Mol. Immunol,
doi:10.1038/s41423-020-00571-xFu, Ye, Feng, Yu, Wang et al., Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease, Nat. Commun,
doi:10.1038/s41467-020-18233-xGao, Gong, Fang, Weng, Wang et al., Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication, PLoS Pathog,
doi:10.1371/journal.ppat.1008690Gao, Yan, Huang, Liu, Zhao et al., Structure of the RNAdependent RNA polymerase from COVID-19 virus, Science,
doi:10.1126/science.abb7498Garcia, Sharma, Ramaiah, Sen, Purkayastha et al., Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication, Cell Rep,
doi:10.1016/j.celrep.2021.108940Ghosh, Brindisi, Shahabi, Chapman, Mesecar, Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics, ChemMedChem,
doi:10.1002/cmdc.202000223Gomes, Santana, Marcolino, Lima, Melo-Minardi et al., Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics, PLoS One,
doi:10.1371/journal.pone.0267471Gordon, Jang, Bouhaddou, Xu, Obernier et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature,
doi:10.1038/s41586-020-2286-9Graham, Baric, Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission, J. Virol,
doi:10.1128/JVI.01394-09Group, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet,
doi:10.1016/S0140-6736(20)32013-4Guo, Cao, Hong, Tan, Chen et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status, in eng, Mil Med Res,
doi:10.1186/s40779-020-00240-0Harrison, Lancaster, Rhodes, A matter of time": evidence-making temporalities of vaccine development in the COVID-19 media landscape, Time Soc,
doi:10.1177/0961463X211032201Hasan, Paray, Hussain, Qadir, Attar et al., A review on the cleavage priming of the spike protein on coronavirus by angiotensinconverting enzyme-2 and furin, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1754293Heilmann, Costacurta, Moghadasi, Ye, Pavan et al., SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376, Sci. Transl. Med
Henß, Beck, Weidner, Biedenkopf, Sliva et al., Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry, Virol. J,
doi:10.1186/s12985-016-0607-2Hoffman, Kania, Brothers, Davies, Ferre et al., Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19, J. Med. Chem,
doi:10.1021/acs.jmedchem.0c01063Holst, Nowak, Hoch, Cannabidiol as a treatment for COVID-19 symptoms? A critical review, Cannabis Cannabinoid Res,
doi:10.1089/can.2021.0135Hu, Jo, Degrado, Wang, Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell, J. Med. Virol,
doi:10.1002/jmv.27616Huang, Lokugamage, Rozovics, Narayanan, Semler et al., SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage, PLoS Pathog,
doi:10.1371/journal.ppat.1002433Iketani, Mohri, Culbertson, Hong, Duan et al., Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir, Nature
Jager, Hoffmann, Pohlmann, Kruger, Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses, Viruses,
doi:10.3390/v14071526Ji, Li, Medicinal chemistry strategies toward host targeting antiviral agents, Med. Res. Rev,
doi:10.1002/med.21664Jiang, Liu, Manning, Bonahoom, Lotvola et al., Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1828172Jiang, Yin, Xu, RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2020.08.116Jin, Zhao, Sun, Zhang, Wang et al., Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur, Nat. Struct. Mol. Biol,
doi:10.1038/s41594-020-0440-6Johnson, Brasel, Massey, Garron, Grimes et al., Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model, Antiviral Res,
doi:10.1016/j.antiviral.2022.105492Jourdan, Bureau, Rochais, Dallemagne, Drug repositioning: a brief overview, J. Pharm. Pharmacol,
doi:10.1111/jphp.13273Jungreis, Sealfon, Kellis, SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes, Nat. Commun,
doi:10.1038/s41467-021-22905-7Kang, Jang, Lee, Jin, Jun et al., Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur, Eur. J. Med. Chem,
doi:10.1016/j.ejmech.2023.115720Katopodis, Randeva, Spandidos, Saravi, Kyrou et al., Host cell entry mediators implicated in the cellular tropism of SARS-CoV-2, the pathophysiology of COVID-19 and the identification of microRNAs that can modulate the expression of these mediators, Int. J. Mol. Med,
doi:10.3892/ijmm.2021.5075Khan, Jha, Singh, Jain, Amera et al., Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1814870Klein, Cortese, Winter, Wachsmuth-Melm, Neufeldt et al., SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography, Nat. Commun,
doi:10.1038/s41467-020-19619-7Kokic, Hillen, Tegunov, Dienemann, Seitz et al., Mechanism of SARS-CoV-2 polymerase stalling by remdesivir, Nat. Commun,
doi:10.1038/s41467-020-20542-0Kumar, Gupta, Zak, Upadhyay, Sharma et al., A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): in silico and in vitro investigations, RSC Med. Chem,
doi:10.1039/d1md00202cLabouta, Langer, Cullis, Merkel, Prausnitz et al., Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective, Drug Deliv Transl Res,
doi:10.1007/s13346-022-01146-1Li, Gui, Liang, Sall, Zhang et al., The REEP5/TRAM1 complex binds SARS-CoV-2 NSP3 and promotes virus replication, J. Virol
Li, Guo, Tian, Wang, Yang et al., Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis, Med,
doi:10.1016/j.medj.2020.07.002Li, Kang, Progress in developing inhibitors of SARS-CoV-2 3C-like protease, Microorganisms
Lin, Tsai, Hsu, Ho, Wang et al., Study of baicalin toward COVID-19 Treatment: in silico target analysis and in vitro inhibitory effects on SARS-CoV-2 proteases, Biomed. Hub
Liu, Iketani, Zask, Khanizeman, Bednarova et al., Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19, Nat. Commun
Liu, Liu, Fan, Kehriman, Zhang et al., Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis, Eur. J. Med. Res,
doi:10.1186/s40001-023-01048-zLiu, Ye, Sun, Liang, Li et al., Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro, J. Enzym. Inhib. Med. Chem
Loffredo, Lucero, Chen, O'connell, Bergqvist et al., The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication, Sci. Rep,
doi:10.1038/s41598-021-84782-wLowery, Sariol, Perlman, Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19, Cell Host Microbe,
doi:10.1016/j.chom.2021.05.004Luvira, Schilling, Jittamala, Watson, Boyd et al., Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an openlabel, randomised, controlled, adaptive platform trial, BMC Infect. Dis,
doi:10.1186/s12879-023-08835-3Ma, Hu, Townsend, Lagarias, Marty et al., Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors, in eng, ACS Pharmacol. Transl. Sci,
doi:10.1021/acsptsci.0c00130Ma, Sacco, Hurst, Townsend, Hu et al., Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease, in eng, Cell Res,
doi:10.1038/s41422-020-0356-zMa, Sacco, Xia, Lambrinidis, Townsend et al., Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of highthroughput screening and a FlipGFP-based reporter assay, in eng, ACS Cent. Sci,
doi:10.1021/acscentsci.1c00519Ma, Tan, Choza, Wang, Wang, Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays, Acta Pharm. Sin. B,
doi:10.1016/j.apsb.2021.10.026Ma, Wang, Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors, ACS Pharmacol. Transl. Sci,
doi:10.1021/acsptsci.1c00240Machitani, Yasukawa, Nakashima, Furuichi, Masutomi, RNAdependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19, Cancer Sci,
doi:10.1111/cas.14618Mali, Eerike, Raj, Bisoi, Priyadarshini et al., Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review, Ir. J. Med. Sci,
doi:10.1007/s11845-022-03139-yMalone, Urakova, Snijder, Campbell, Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design, in eng, Nat. Rev. Mol. Cell Biol,
doi:10.1038/s41580-021-00432-zManfredonia, Nithin, Ponce-Salvatierra, Ghosh, Wirecki et al., Genome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically-relevant elements, Nucleic Acids Res,
doi:10.1093/nar/gkaa1053Mazinani, Rude, The novel zoonotic Coronavirus disease 2019 (COVID-19) pandemic: health perspective on the outbreak, J Healthc Qual Res,
doi:10.1016/j.jhqr.2020.09.004Mccaskill, Singhania, Burgess, Allavena, Wu et al., Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA, Mol. Ther. Nucleic Acids,
doi:10.1038/mtna.2013.22Mehta, Ciurtin, Scully, Levi, Chambers, JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk, in eng, Eur. Respir. J,
doi:10.1183/13993003.01919-2020Mei, Zhang, He, Zhang, Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand, in eng, J. Hematol. Oncol,
doi:10.1186/s13045-019-0733-6Mengist, Mekonnen, Mohammed, Shi, Jin, Potency, safety, and pharmacokinetic profiles of potential inhibitors targeting SARS-CoV-2 main protease, Front. Pharmacol,
doi:10.3389/fphar.2020.630500Mielech, Chen, Mesecar, Baker, Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities, Virus Res,
doi:10.1016/j.virusres.2014.01.025Moghadasi, Heilmann, Khalil, Nnabuife, Kearns et al., Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors, Sci. Adv
Moreira, Guzman, Boopathi, Baker, Poma, Characterization of structural and energetic differences between conformations of the SARS-CoV-2 spike protein, Materials,
doi:10.3390/ma13235362Morse, Lalonde, Xu, Liu, Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV, Chembiochem,
doi:10.1002/cbic.202000047Mota, Sant'ana Filho, Hendrickson, Devay, Donne et al., Safety and effeicacy of Disulfiram in Hospitalized patients with moderate COVID-19: a randomized, double-blinded, placebo-controlled trial, medRxiv,
doi:10.1101/2023.10.25.23297554Mukherjee, Bhattacharya, Bojkova, Mehdipour, Shin et al., Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection, J. Biol. Chem,
doi:10.1016/j.jbc.2021.100925Munshi, Neupane, Ileperuma, Halma, Kelly et al., Identifying inhibitors of -1 programmed ribosomal frameshifting in a broad spectrum of coronaviruses, Viruses,
doi:10.3390/v14020177Muratov, Amaro, Andrade, Brown, Ekins et al., A critical overview of computational approaches employed for COVID-19 drug discovery, Chem. Soc. Rev,
doi:10.1039/d0cs01065kMuthumalage, Rahman, Cannabidiol differentially regulates basal and LPSinduced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts, Toxicol. Appl. Pharmacol,
doi:10.1016/j.taap.2019.114713Mutlu, Ugurel, Sariyer, Ata, Inci et al., Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1819882Naik, Bharadwaj, Dingelstad, Kalyaanamoorthy, Mandal et al., Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2, in eng, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2021.1891969Naqvi, Fatima, Mohammad, Fatima, Singh et al., Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach, Biochim. Biophys. Acta, Mol. Basis Dis,
doi:10.1016/j.bbadis.2020.165878Ndoutoume, Kombe, Augustin, Biteghe, Development of a Novel Anti-SARS-CoV-2 Antiviral: Eff Ective Inhibitory Activity of Brilacidin,
doi:10.37871/jbres1504Newman, Douangamath, Yadzani, Yosaatmadja, Aimon et al., Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase, Nat. Commun,
doi:10.1038/s41467-021-25166-6Nguyen, Yang, Nicolaescu, Best, Gula et al., Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses, Sci. Adv,
doi:10.1126/sciadv.abi6110Nickbakhsh, Ho, Marques, Mcmenamin, Gunson et al., Epidemiology of seasonal coronaviruses: establishing the context for the emergence of coronavirus disease 2019, J. Infect. Dis,
doi:10.1093/infdis/jiaa185Nieto-Torres, Dediego, Verdia-Baguena, Jimenez-Guardeno, Regla-Nava et al., Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis, PLoS Pathog,
doi:10.1371/journal.ppat.1004077Nogara, Omage, Bolzan, Delgado, Orian et al., Reactivity and binding mode of disulfiram, its metabolites, and derivatives in SARS-CoV-2 PLpro: insights from computational chemistry studies, J. Mol. Model
Noske, De Souza Silva, De Godoy, Dolci, Fernandes et al., Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease, J. Biol. Chem,
doi:10.1016/j.jbc.2023.103004Ogando, Dalebout, Zevenhoven-Dobbe, Limpens, Van Der Meer et al., SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology, J. Gen. Virol,
doi:10.1099/jgv.0.001453Owen, Allerton, Anderson, Aschenbrenner, Avery et al., An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science,
doi:10.1126/science.abl4784Parida, Paul, Chakravorty, Nature's therapy for COVID-19: targeting the vital non-structural proteins (NSP) from SARS-CoV-2 with phytochemicals from Indian medicinal plants, Phytomed Plus,
doi:10.1016/j.phyplu.2020.100002Peng, Peng, Yuan, Zhao, Wang et al., Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2, Cell Rep,
doi:10.1016/j.celrep.2020.107774Pinke, Zorzella-Pezavento, De Campos Fraga-Silva, Mimura, De Oliveira et al., Calming down mast cells with ketotifen: a potential strategy for multiple sclerosis therapy?, Neurotherapeutics,
doi:10.1007/s13311-019-00775-8Pirola, Patanè, Biological mechanisms of transplacental SARS-COV-2 transmission
Pitts, Li, Perry, Du Pont, Riola et al., Remdesivir and GS-441524 retain antiviral activity against delta, Omicron, and other emergent SARS-CoV-2 variants, Antimicrob. Agents Chemother,
doi:10.1128/aac.00222-22Plaze, Attali, Prot, Petit, Blatzer et al., Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.106274Poduri, Joshi, Jagadeesh, Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19, Cell. Signal,
doi:10.1016/j.cellsig.2020.109721Pokhrel, Chapagain, Siltberg-Liberles, Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2, in eng, J. Med. Microbiol,
doi:10.1099/jmm.0.001203Pourkarim, Pourtaghi-Anvarian, Rezaee, Molnupiravir: a new candidate for COVID-19 treatment, Pharmacol Res Perspect,
doi:10.1002/prp2.909Qiao, Li, Zeng, Liu, Luo et al., SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model, Science
Raj, Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing, Biochem Biophys Rep,
doi:10.1016/j.bbrep.2020.100847Raman, Chaudhary, Shieh, Eosinophilic pneumonia: a case of daptomycin induced lung injury, J. Community Hosp. Intern. Med. Perspect,
doi:10.1080/20009666.2021.1883813Ramirez-Ponce, Flores, Barrella, Ales, Ketotifen is a microglial stabilizer by inhibiting secretory vesicle acidification, Life Sci,
doi:10.1016/j.lfs.2023.121537Ratia, Pegan, Takayama, Sleeman, Coughlin et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.0805240105Reggiori, Monastyrska, Verheije, Cali, Ulasli et al., Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication, Cell Host Microbe,
doi:10.1016/j.chom.2010.05.013Ren, Shang, Yin, Ge, Wang et al., A multitargeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors, Acta Pharmacol. Sin,
doi:10.1038/s41401-021-00668-7Ren, Zou, Bailly, Xu, Zeng et al., The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo, in eng, Emerg Microbes Infect,
doi:10.1038/emi.2014.60Rodrigues, Bento Cunha, Vassilevskaia, Viveiros, Cunha, Drug repurposing for COVID-19: a review and a novel strategy to identify new targets and potential drug candidates, Molecules,
doi:10.3390/molecules27092723Salehi, Khosravi, Salehi, Kheirollahi, Khanahmad, Simple and easy to perform preimplantation genetic diagnosis for beta-thalassemia major using combination of conventional and fluorescent polymerase chain reaction, Adv. Biomed. Res,
doi:10.4103/2277-9175.201682Salgado-Benvindo, Thaler, Tas, Ogando, Bredenbeek et al., Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle, Antimicrob. Agents Chemother,
doi:10.1128/AAC.00900-20Saramago, Costa, Souza, Barria, Domingues et al., The nsp15 nuclease as a good target to combat SARS-CoV-2: mechanism of action and its inactivation with FDA-approved drugs, Microorganisms,
doi:10.3390/microorganisms10020342Sargsyan, Lin, Chen, Grauffel, Chen et al., Multitargeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors, Chem. Sci,
doi:10.1039/d0sc02646hSha, Liu, Hao, Current state-of-the-art and potential future therapeutic drugs against COVID-19, Front. Cell Dev. Biol,
doi:10.3389/fcell.2023.1238027Shah, Orton, Grinsztejn, Donaldson, Ramirez et al., Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care, Lancet Respir. Med,
doi:10.1016/S2213-2600(22)00412-XShannon, Fattorini, Sama, Selisko, Feracci et al., A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase, Nat. Commun,
doi:10.1038/s41467-022-28113-1Sheahan, Sims, Graham, Menachery, Gralinski et al., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, in eng, Sci. Transl. Med,
doi:10.1126/scitranslmed.aal3653Sheikh, Al-Taher, Al-Nazawi, Al-Mubarak, Kandeel, Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design, in eng, J Virol Methods,
doi:10.1016/j.jviromet.2019.113806Shi, Shuai, Wen, Wang, Yan et al., The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract, Emerg Microbes Infect,
doi:10.1080/22221751.2021.1899770Shyr, Cheng, Lo, Zheng, Drug combination therapy for emerging viral diseases, Drug Discov. Today
Silvas, Jureka, Nicolini, Chvatal, Basler, Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication, bioRxiv,
doi:10.1101/2020.07.18.210211Singh, Pathania, Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV, SAR QSAR Environ. Res,
doi:10.1080/1062936X.2020.1825014Siu, Teoh, Lo, Chan, Kien et al., N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles, J. Virol,
doi:10.1128/JVI.01052-08Sl, Overcoming nonstructural protein 15-nidoviral uridylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2, Future Drug Discov,
doi:10.4155/fdd-2020-0012Slanina, Madhugiri, Bylapudi, Schultheiss, Karl et al., Coronavirus replication-transcription complex: vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2022310118Snijder, Limpens, De Wilde, De Jong, Zevenhoven-Dobbe et al., A unifying structural and functional model of the coronavirus replication organelle: tracking down RNA synthesis, PLoS Biol,
doi:10.1371/journal.pbio.3000715Song, Xu, Bao, Zhang, Yu et al., From SARS to MERS, thrusting coronaviruses into the spotlight, Viruses,
doi:10.3390/v11010059Su, Wong, Shi, Liu, Lai et al., Epidemiology, genetic recombination, and pathogenesis of coronaviruses, Trends Microbiol,
doi:10.1016/j.tim.2016.03.003Su, Yao, Zhao, Li, Liu et al., Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients, Acta Pharmacol. Sin,
doi:10.1038/s41401-020-0483-6Swaraj, Malpani, Tripathi, Antagonism and evasion of cellular innate immunity by SARS-CoV-2
Tan, Zhang, Ansari, Jadhav, Tan et al., Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model, bioRxiv,
doi:10.1101/2023.12.01.569653Thomas, Mapping the nonstructural transmembrane proteins of severe acute respiratory syndrome coronavirus 2, J. Comput. Biol,
doi:10.1089/cmb.2020.0627Tian, Feng, Chen, Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2023.106870Tian, Li, Huang, Xia, Lu et al., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg Microbes Infect,
doi:10.1080/22221751.2020.1729069To, Sridhar, Chiu, Hung, Li et al., Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic, Emerg Microbes Infect,
doi:10.1080/22221751.2021.1898291Tvarogova, Madhugiri, Bylapudi, Ferguson, Karl et al., Identification and characterization of a human coronavirus 229E nonstructural protein 8-associated RNA 3'-terminal adenylyltransferase activity, J. Virol,
doi:10.1128/JVI.00291-19Ulasli, Verheije, De Haan, Reggiori, Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus, Cell Microbiol,
doi:10.1111/j.1462-5822.2010.01437.xV'kovski, Gerber, Kelly, Pfaender, Ebert et al., Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling, Elife,
doi:10.7554/eLife.42037V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat. Rev. Microbiol,
doi:10.1038/s41579-020-00468-6Valipour, Different aspects of emetine's capabilities as a highly potent SARS-CoV-2 inhibitor against COVID-19, ACS Pharmacol. Transl. Sci,
doi:10.1021/acsptsci.2c00045Van Der Pol, Aljofan, Blin, Cornel, Rongen et al., Drug repurposing of generic drugs: challenges and the potential role for government, Appl Health Econ Health Policy,
doi:10.1007/s40258-023-00816-6Vardhan, Sahoo, Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations, J Tradit Complement Med,
doi:10.1016/j.jtcme.2021.12.002Wahl, Gralinski, Johnson, Yao, Kovarova et al., SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature,
doi:10.1038/s41586-021-03312-wWalls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell,
doi:10.1016/j.cell.2020.02.058Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Wang, Chen, He, Li, Xiong et al., Structure-based design of potent peptidomimetic inhibitors covalently targeting SARS-CoV-2 papain-like protease, Int. J. Mol. Sci,
doi:10.3390/ijms24108633Wang, Yang, The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection, Nutrients,
doi:10.3390/nu15153443Wang, Yang, Zhao, Co-crystallization and structure determination: an effective direction for anti-SARS-CoV-2 drug discovery, Comput. Struct. Biotechnol. J,
doi:10.1016/j.csbj.2021.08.029Wang, Zhao, Gao, Gao, Wang et al., SARS-CoV-2: structure, biology, and structure-based therapeutics development, Front. Cell. Infect. Microbiol,
doi:10.3389/fcimb.2020.587269Weglarz-Tomczak, Tomczak, Talma, Burda-Grabowska, Giurg et al., Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2, Sci. Rep,
doi:10.1038/s41598-021-83229-6Wilson, Frazier, Li, Randall, Stanley, Biochemical characterization of emerging SARS-CoV-2 Nsp15 endoribonuclease variants, bioRxiv,
doi:10.1101/2022.05.10.491349Wolff, Limpens, Zevenhoven-Dobbe, Laugks, Zheng et al., A molecular pore spans the double membrane of the coronavirus replication organelle, Science,
doi:10.1126/science.abd3629Wrapp, Wang, Corbett, Goldsmith, Hsieh et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science,
doi:10.1126/science.abb2507Wu, Liu, Yang, Zhang, Zhong et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B,
doi:10.1016/j.apsb.2020.02.008Wu, Yin, Jiang, Xu, Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19, Acta Pharmacol. Sin,
doi:10.1038/s41401-021-00851-wWu, Zhao, Yu, Chen, Wang et al., A new coronavirus associated with human respiratory disease in China, in eng, Nature,
doi:10.1038/s41586-020-2008-3Wu, Zhou, Lv, Zheng, Wu et al., Phase I, single-dose study to assess the pharmacokinetics and safety of suramin in healthy Chinese volunteers, Drug Des Devel Ther,
doi:10.2147/DDDT.S416325Xiang, Wang, Qu, Lv, Han et al., The efficacy and safety of nirmatrelvir/ritonavir against COVID-19 in elderly patients, Int. J. Gen. Med
Xu, Wang, Honnen, Pinter, Weston et al., Brilacidin, a non-peptide defensin-mimetic molecule, inhibits SARS-CoV-2 infection by blocking viral entry, in eng, EC Microbiol
Yadav, Chaudhary, Jain, Chaudhary, Khanra et al., Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19, Cells,
doi:10.3390/cells10040821Yamato, Kinoshita, Miyazawa, Seki, Mizuno et al., Ensitrelvir in patients with SARS-CoV-2: a retrospective chart review, J. Infect. Chemother
Yang, Petitjean, Koehler, Zhang, Dumitru et al., Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor, Nat. Commun,
doi:10.1038/s41467-020-18319-6Yin, Luan, Li, Zhou, Wang et al., Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin, Nat. Struct. Mol. Biol,
doi:10.1038/s41594-021-00570-0Yin, Mao, Luan, Shen, Shen et al., Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science,
doi:10.1126/science.abc1560Yotsuyanagi, Ohmagari, Doi, Imamura, Sonoyama et al., A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part), Medicine
Yuen, Lam, Wong, Mak, Wang et al., SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists, Emerg Microbes Infect,
doi:10.1080/22221751.2020.1780953Zamore, Tuschl, Sharp, Bartel, RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals, Cell,
doi:10.1016/s0092-8674(00)80620-0Zhang, Lin, Kusov, Nian, Ma et al., α-Ketoamides as broadspectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment, J. Med. Chem
Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors, Science
Zhao, Qiu, Aryal, Hackett, Wang, The RNA architecture of the SARS-CoV-2 3'-untranslated region, Viruses,
doi:10.3390/v12121473Zhou, Gammeltoft, Ryberg, Pham, Tjørnelund et al., Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system, Sci. Adv
Zhou, Yang, Wang, Hu, Zhang et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, in eng, Nature,
doi:10.1038/s41586-020-2012-7Zhu, Zhang, Wang, Li, Yang et al., A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med,
doi:10.1056/NEJMoa2001017Zimmer, Kibe, Rand, Pekarek, Ye et al., The short isoform of the host antiviral protein ZAP acts as an inhibitor of SARS-CoV-2 programmed ribosomal frameshifting, in eng, Nat. Commun,
doi:10.1038/s41467-021-27431-0Znaidia, Demeret, Van Der Werf, Komarova, Characterization of SARS-CoV-2 evasion: interferon pathway and therapeutic options, Viruses,
doi:10.3390/v14061247{ 'indexed': {'date-parts': [[2024, 7, 27]], 'date-time': '2024-07-27T00:25:36Z', 'timestamp': 1722039936517},
'reference-count': 246,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2024, 10, 1]],
'date-time': '2024-10-01T00:00:00Z',
'timestamp': 1727740800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2024, 10, 1]],
'date-time': '2024-10-01T00:00:00Z',
'timestamp': 1727740800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/legal/tdmrep-license'},
{ 'start': { 'date-parts': [[2024, 7, 15]],
'date-time': '2024-07-15T00:00:00Z',
'timestamp': 1721001600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'funder': [ { 'DOI': '10.13039/501100013804',
'name': 'Fundamental Research Funds for the Central Universities',
'doi-asserted-by': 'publisher'},
{ 'DOI': '10.13039/501100001809',
'name': 'National Natural Science Foundation of China',
'doi-asserted-by': 'publisher'}],
'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 10]]},
'DOI': '10.1016/j.mcp.2024.101973',
'type': 'journal-article',
'created': {'date-parts': [[2024, 7, 24]], 'date-time': '2024-07-24T02:02:44Z', 'timestamp': 1721786564000},
'page': '101973',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'special_numbering': 'C',
'title': 'SARS-CoV-2 replication and drug discovery',
'prefix': '10.1016',
'volume': '77',
'author': [ {'given': 'Farah', 'family': 'Nazir', 'sequence': 'first', 'affiliation': []},
{'given': 'Arnaud', 'family': 'John Kombe Kombe', 'sequence': 'additional', 'affiliation': []},
{'given': 'Zunera', 'family': 'Khalid', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shaheen', 'family': 'Bibi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hongliang', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Songquan', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tengchuan', 'family': 'Jin', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'issue': '7798',
'key': '10.1016/j.mcp.2024.101973_bib1',
'doi-asserted-by': 'crossref',
'first-page': '270',
'DOI': '10.1038/s41586-020-2012-7',
'article-title': 'A pneumonia outbreak associated with a new coronavirus of probable bat '
'origin',
'volume': '579',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Nature'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib2',
'doi-asserted-by': 'crossref',
'first-page': '727',
'DOI': '10.1056/NEJMoa2001017',
'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019',
'volume': '382',
'author': 'Zhu',
'year': '2020',
'journal-title': 'N. Engl. J. Med.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib3',
'doi-asserted-by': 'crossref',
'first-page': '490',
'DOI': '10.1016/j.tim.2016.03.003',
'article-title': 'Epidemiology, genetic recombination, and pathogenesis of coronaviruses',
'volume': '24',
'author': 'Su',
'year': '2016',
'journal-title': 'Trends Microbiol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib4',
'doi-asserted-by': 'crossref',
'first-page': '382',
'DOI': '10.1080/22221751.2020.1729069',
'article-title': 'Potent binding of 2019 novel coronavirus spike protein by a SARS '
'coronavirus-specific human monoclonal antibody',
'volume': '9',
'author': 'Tian',
'year': '2020',
'journal-title': 'Emerg Microbes Infect'},
{ 'issue': '10223',
'key': '10.1016/j.mcp.2024.101973_bib5',
'doi-asserted-by': 'crossref',
'first-page': '507',
'DOI': '10.1016/S0140-6736(20)30211-7',
'article-title': 'Epidemiological and clinical characteristics of 99 cases of 2019 novel '
'coronavirus pneumonia in Wuhan, China: a descriptive study',
'volume': '395',
'author': 'Chen',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': '10.1016/j.mcp.2024.101973_bib6',
'article-title': 'Bioactive natural products in COVID-19 therapy',
'volume': '13',
'author': 'Wang',
'year': '2022',
'journal-title': 'Front. Pharmacol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib7',
'doi-asserted-by': 'crossref',
'first-page': '47',
'DOI': '10.1016/j.jhqr.2020.09.004',
'article-title': 'The novel zoonotic Coronavirus disease 2019 (COVID-19) pandemic: health '
'perspective on the outbreak',
'volume': '36',
'author': 'Mazinani',
'year': '2021',
'journal-title': 'J Healthc Qual Res'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib8',
'doi-asserted-by': 'crossref',
'first-page': '3134',
'DOI': '10.1128/JVI.01394-09',
'article-title': 'Recombination, reservoirs, and the modular spike: mechanisms of '
'coronavirus cross-species transmission',
'volume': '84',
'author': 'Graham',
'year': '2010',
'journal-title': 'J. Virol.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib9',
'doi-asserted-by': 'crossref',
'first-page': '181',
'DOI': '10.1038/s41579-018-0118-9',
'article-title': 'Origin and evolution of pathogenic coronaviruses',
'volume': '17',
'author': 'Cui',
'year': '2019',
'journal-title': 'Nat. Rev. Microbiol.'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib10',
'doi-asserted-by': 'crossref',
'first-page': '533',
'DOI': '10.1016/S1473-3099(20)30120-1',
'article-title': 'An interactive web-based dashboard to track COVID-19 in real time',
'volume': '20',
'author': 'Dong',
'year': '2020',
'journal-title': 'Lancet Infect. Dis.'},
{ 'issue': '21',
'key': '10.1016/j.mcp.2024.101973_bib11',
'doi-asserted-by': 'crossref',
'first-page': '11727',
'DOI': '10.1073/pnas.2003138117',
'article-title': 'Cell entry mechanisms of SARS-CoV-2',
'volume': '117',
'author': 'Shang',
'year': '2020',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib12',
'doi-asserted-by': 'crossref',
'DOI': '10.3892/ijmm.2021.5075',
'article-title': 'Host cell entry mediators implicated in the cellular tropism of '
'SARS-CoV-2, the pathophysiology of COVID-19 and the identification of '
'microRNAs that can modulate the expression of these mediators',
'volume': '49',
'author': 'Katopodis',
'year': '2022',
'journal-title': 'Int. J. Mol. Med.'},
{ 'issue': '15',
'key': '10.1016/j.mcp.2024.101973_bib13',
'doi-asserted-by': 'crossref',
'first-page': '3443',
'DOI': '10.3390/nu15153443',
'article-title': 'The therapeutic potential of natural dietary flavonoids against '
'SARS-CoV-2 infection',
'volume': '15',
'author': 'Wang',
'year': '2023',
'journal-title': 'Nutrients'},
{ 'issue': '7807',
'key': '10.1016/j.mcp.2024.101973_bib14',
'doi-asserted-by': 'crossref',
'first-page': '221',
'DOI': '10.1038/s41586-020-2179-y',
'article-title': 'Structural basis of receptor recognition by SARS-CoV-2',
'volume': '581',
'author': 'Shang',
'year': '2020',
'journal-title': 'Nature'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib15',
'doi-asserted-by': 'crossref',
'first-page': '4541',
'DOI': '10.1038/s41467-020-18319-6',
'article-title': 'Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 '
'receptor',
'volume': '11',
'author': 'Yang',
'year': '2020',
'journal-title': 'Nat. Commun.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib16',
'doi-asserted-by': 'crossref',
'first-page': '4684',
'DOI': '10.1016/j.csbj.2021.08.029',
'article-title': 'Co-crystallization and structure determination: an effective direction '
'for anti-SARS-CoV-2 drug discovery',
'volume': '19',
'author': 'Wang',
'year': '2021',
'journal-title': 'Comput. Struct. Biotechnol. J.'},
{ 'issue': '7819',
'key': '10.1016/j.mcp.2024.101973_bib17',
'doi-asserted-by': 'crossref',
'first-page': '154',
'DOI': '10.1038/s41586-020-2368-8',
'article-title': 'Structure of replicating SARS-CoV-2 polymerase',
'volume': '584',
'author': 'Hillen',
'year': '2020',
'journal-title': 'Nature'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib18',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pbio.3000715',
'article-title': 'A unifying structural and functional model of the coronavirus '
'replication organelle: tracking down RNA synthesis',
'volume': '18',
'author': 'Snijder',
'year': '2020',
'journal-title': 'PLoS Biol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib19',
'doi-asserted-by': 'crossref',
'first-page': '279',
'DOI': '10.1038/s41467-020-20542-0',
'article-title': 'Mechanism of SARS-CoV-2 polymerase stalling by remdesivir',
'volume': '12',
'author': 'Kokic',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib20',
'doi-asserted-by': 'crossref',
'first-page': '132',
'DOI': '10.1177/0961463X211032201',
'article-title': 'A matter of time": evidence-making temporalities of vaccine development '
'in the COVID-19 media landscape',
'volume': '31',
'author': 'Harrison',
'year': '2022',
'journal-title': 'Time Soc.'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib21',
'article-title': 'Vaccine development throughout history',
'volume': '13',
'author': 'Saleh',
'year': '2021',
'journal-title': 'Cureus'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib22',
'doi-asserted-by': 'crossref',
'first-page': '673',
'DOI': '10.1038/nrd1468',
'article-title': 'Drug repositioning: identifying and developing new uses for existing '
'drugs',
'volume': '3',
'author': 'Ashburn',
'year': '2004',
'journal-title': 'Nat. Rev. Drug Discov.'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib23',
'doi-asserted-by': 'crossref',
'first-page': '1145',
'DOI': '10.1111/jphp.13273',
'article-title': 'Drug repositioning: a brief overview',
'volume': '72',
'author': 'Jourdan',
'year': '2020',
'journal-title': 'J. Pharm. Pharmacol.'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib24',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/molecules27092723',
'article-title': 'Drug repurposing for COVID-19: a review and a novel strategy to '
'identify new targets and potential drug candidates',
'volume': '27',
'author': 'Rodrigues',
'year': '2022',
'journal-title': 'Molecules'},
{ 'key': '10.1016/j.mcp.2024.101973_bib25',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fphar.2021.704205',
'article-title': 'The drug repurposing for COVID-19 clinical trials provide very '
'effective therapeutic combinations: lessons learned from major clinical '
'studies',
'volume': '12',
'author': 'Chakraborty',
'year': '2021',
'journal-title': 'Front. Pharmacol.'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib26',
'doi-asserted-by': 'crossref',
'first-page': '865',
'DOI': '10.1016/j.tim.2018.04.004',
'article-title': 'Drug repurposing for viral infectious diseases: how far are we?',
'volume': '26',
'author': 'Mercorelli',
'year': '2018',
'journal-title': 'Trends Microbiol.'},
{ 'issue': '6492',
'key': '10.1016/j.mcp.2024.101973_bib27',
'doi-asserted-by': 'crossref',
'first-page': '779',
'DOI': '10.1126/science.abb7498',
'article-title': 'Structure of the RNA-dependent RNA polymerase from COVID-19 virus',
'volume': '368',
'author': 'Gao',
'year': '2020',
'journal-title': 'Science'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib28',
'doi-asserted-by': 'crossref',
'first-page': '821',
'DOI': '10.3390/cells10040821',
'article-title': 'Role of structural and non-structural proteins and therapeutic targets '
'of SARS-CoV-2 for COVID-19',
'volume': '10',
'author': 'Yadav',
'year': '2021',
'journal-title': 'Cells'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib29',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/v11010059',
'article-title': 'From SARS to MERS, thrusting coronaviruses into the spotlight',
'volume': '11',
'author': 'Song',
'year': '2019',
'journal-title': 'Viruses'},
{ 'key': '10.1016/j.mcp.2024.101973_bib30',
'article-title': 'Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for '
'computational drug designing',
'volume': '25',
'author': 'Raj',
'year': '2021',
'journal-title': '(in eng), Biochem Biophys Rep'},
{ 'issue': '7798',
'key': '10.1016/j.mcp.2024.101973_bib31',
'doi-asserted-by': 'crossref',
'first-page': '265',
'DOI': '10.1038/s41586-020-2008-3',
'article-title': 'A new coronavirus associated with human respiratory disease in China',
'volume': '579',
'author': 'Wu',
'year': '2020',
'journal-title': 'Nature'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib32',
'doi-asserted-by': 'crossref',
'first-page': '1052',
'DOI': '10.1016/j.chom.2021.05.004',
'article-title': 'Innate immune and inflammatory responses to SARS-CoV-2: implications '
'for COVID-19',
'volume': '29',
'author': 'Lowery',
'year': '2021',
'journal-title': 'Cell Host Microbe'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib33',
'doi-asserted-by': 'crossref',
'first-page': '909',
'DOI': '10.1089/cmb.2020.0627',
'article-title': 'Mapping the nonstructural transmembrane proteins of severe acute '
'respiratory syndrome coronavirus 2',
'volume': '28',
'author': 'Thomas',
'year': '2021',
'journal-title': 'J. Comput. Biol.'},
{ 'issue': '7816',
'key': '10.1016/j.mcp.2024.101973_bib34',
'doi-asserted-by': 'crossref',
'first-page': '459',
'DOI': '10.1038/s41586-020-2286-9',
'article-title': 'A SARS-CoV-2 protein interaction map reveals targets for drug '
'repurposing',
'volume': '583',
'author': 'Gordon',
'year': '2020',
'journal-title': 'Nature'},
{ 'key': '10.1016/j.mcp.2024.101973_bib35',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fgene.2020.572702',
'article-title': 'A comprehensive analysis of cis-acting RNA elements in the SARS-CoV-2 '
'genome by a bioinformatics approach',
'volume': '11',
'author': 'Ahmed',
'year': '2020',
'journal-title': 'Front. Genet.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib36',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/mmbr.00057-21',
'article-title': 'Lessons learned and yet-to-Be learned on the importance of RNA '
'structure in SARS-CoV-2 replication',
'volume': '86',
'author': 'Bassett',
'year': '2022',
'journal-title': 'Microbiol. Mol. Biol. Rev.'},
{ 'issue': '12',
'key': '10.1016/j.mcp.2024.101973_bib37',
'doi-asserted-by': 'crossref',
'first-page': '1473',
'DOI': '10.3390/v12121473',
'article-title': "The RNA architecture of the SARS-CoV-2 3'-untranslated region",
'volume': '12',
'author': 'Zhao',
'year': '2020',
'journal-title': 'Viruses'},
{ 'issue': '22',
'key': '10.1016/j.mcp.2024.101973_bib38',
'doi-asserted-by': 'crossref',
'first-page': '12436',
'DOI': '10.1093/nar/gkaa1053',
'article-title': 'Genome-wide mapping of SARS-CoV-2 RNA structures identifies '
'therapeutically-relevant elements',
'volume': '48',
'author': 'Manfredonia',
'year': '2020',
'journal-title': 'Nucleic Acids Res.'},
{ 'issue': '12',
'key': '10.1016/j.mcp.2024.101973_bib39',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.ppat.1002433',
'article-title': 'SARS coronavirus nsp1 protein induces template-dependent '
'endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to '
'nsp1-induced RNA cleavage',
'volume': '7',
'author': 'Huang',
'year': '2011',
'journal-title': 'PLoS Pathog.'},
{ 'issue': '12',
'key': '10.1016/j.mcp.2024.101973_bib40',
'doi-asserted-by': 'crossref',
'first-page': '3021',
'DOI': '10.1038/s41401-021-00851-w',
'article-title': 'Structure genomics of SARS-CoV-2 and its Omicron variant: drug design '
'templates for COVID-19',
'volume': '43',
'author': 'Wu',
'year': '2022',
'journal-title': 'Acta Pharmacol. Sin.'},
{ 'issue': '19',
'key': '10.1016/j.mcp.2024.101973_bib41',
'doi-asserted-by': 'crossref',
'first-page': '10314',
'DOI': '10.1128/JVI.00842-09',
'article-title': 'Severe acute respiratory syndrome coronavirus nonstructural protein 2 '
'interacts with a host protein complex involved in mitochondrial '
'biogenesis and intracellular signaling',
'volume': '83',
'author': 'Cornillez-Ty',
'year': '2009',
'journal-title': 'J. Virol.'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib42',
'doi-asserted-by': 'crossref',
'first-page': '925',
'DOI': '10.1099/jgv.0.001453',
'article-title': 'SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, '
'rapid adaptation and cytopathology',
'volume': '101',
'author': 'Ogando',
'year': '2020',
'journal-title': 'J. Gen. Virol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib43',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fcimb.2020.587269',
'article-title': 'SARS-CoV-2: structure, biology, and structure-based therapeutics '
'development',
'volume': '10',
'author': 'Wang',
'year': '2020',
'journal-title': 'Front. Cell. Infect. Microbiol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib44',
'doi-asserted-by': 'crossref',
'first-page': '184',
'DOI': '10.1016/j.virusres.2014.01.025',
'article-title': 'Nidovirus papain-like proteases: multifunctional enzymes with protease, '
'deubiquitinating and deISGylating activities',
'volume': '194',
'author': 'Mielech',
'year': '2014',
'journal-title': 'Virus Res.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib45',
'doi-asserted-by': 'crossref',
'first-page': 'e24',
'DOI': '10.1016/j.jinf.2020.03.058',
'article-title': 'Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural '
'Protein 6 (NSP6) could affect viral autophagy',
'volume': '81',
'author': 'Benvenuto',
'year': '2020',
'journal-title': 'J. Infect.'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib46',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.celrep.2020.107774',
'article-title': 'Structural and biochemical characterization of the nsp12-nsp7-nsp8 core '
'polymerase complex from SARS-CoV-2',
'volume': '31',
'author': 'Peng',
'year': '2020',
'journal-title': 'Cell Rep.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib47',
'doi-asserted-by': 'crossref',
'first-page': '918',
'DOI': '10.1080/07391102.2020.1819882',
'article-title': 'Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and '
'investigational drugs: an in silico structure-based approach',
'volume': '40',
'author': 'Mutlu',
'year': '2022',
'journal-title': 'J. Biomol. Struct. Dyn.'},
{ 'issue': '12',
'key': '10.1016/j.mcp.2024.101973_bib48',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/JVI.00291-19',
'article-title': 'Identification and characterization of a human coronavirus 229E '
"nonstructural protein 8-associated RNA 3'-terminal adenylyltransferase "
'activity',
'volume': '93',
'author': 'Tvarogova',
'year': '2019',
'journal-title': 'J. Virol.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib49',
'doi-asserted-by': 'crossref',
'DOI': '10.1073/pnas.2022310118',
'article-title': 'Coronavirus replication-transcription complex: vital and selective '
'NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit',
'volume': '118',
'author': 'Slanina',
'year': '2021',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib50',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.isci.2020.101258',
'article-title': 'Crystal structure of the SARS-CoV-2 non-structural protein 9, Nsp9',
'volume': '23',
'author': 'Littler',
'year': '2020',
'journal-title': 'iScience'},
{ 'key': '10.1016/j.mcp.2024.101973_bib51',
'doi-asserted-by': 'crossref',
'first-page': '59',
'DOI': '10.1016/bs.aivir.2016.08.008',
'article-title': 'The nonstructural proteins directing coronavirus RNA synthesis and '
'processing',
'volume': '96',
'author': 'Snijder',
'year': '2016',
'journal-title': 'Adv. Virus Res.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib52',
'doi-asserted-by': 'crossref',
'first-page': '47',
'DOI': '10.1016/j.bbrc.2020.08.116',
'article-title': 'RNA-dependent RNA polymerase: structure, mechanism, and drug discovery '
'for COVID-19',
'volume': '538',
'author': 'Jiang',
'year': '2021',
'journal-title': 'Biochem. Biophys. Res. Commun.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib53',
'doi-asserted-by': 'crossref',
'first-page': '224',
'DOI': '10.1016/j.tim.2020.12.007',
'article-title': 'Dysregulation of cell signaling by SARS-CoV-2',
'volume': '29',
'author': 'Suryawanshi',
'year': '2021',
'journal-title': 'Trends Microbiol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib54',
'doi-asserted-by': 'crossref',
'first-page': '507',
'DOI': '10.1080/22221751.2021.1898291',
'article-title': 'Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 '
'pandemic',
'volume': '10',
'author': 'To',
'year': '2021',
'journal-title': 'Emerg Microbes Infect'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib55',
'doi-asserted-by': 'crossref',
'first-page': '621',
'DOI': '10.1038/s41467-022-28113-1',
'article-title': 'A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase',
'volume': '13',
'author': 'Shannon',
'year': '2022',
'journal-title': 'Nat. Commun.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib56',
'doi-asserted-by': 'crossref',
'first-page': '4848',
'DOI': '10.1038/s41467-021-25166-6',
'article-title': 'Structure, mechanism and crystallographic fragment screening of the '
'SARS-CoV-2 NSP13 helicase',
'volume': '12',
'author': 'Newman',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib57',
'doi-asserted-by': 'crossref',
'first-page': '44',
'DOI': '10.1016/j.jtcme.2021.12.002',
'article-title': 'Exploring the therapeutic nature of limonoids and triterpenoids against '
'SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular '
'docking and dynamics simulations',
'volume': '12',
'author': 'Vardhan',
'year': '2022',
'journal-title': 'J Tradit Complement Med'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib58',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.bbadis.2020.165878',
'article-title': 'Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and '
'therapies: structural genomics approach',
'volume': '1866',
'author': 'Naqvi',
'year': '2020',
'journal-title': 'Biochim. Biophys. Acta, Mol. Basis Dis.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib59',
'doi-asserted-by': 'crossref',
'first-page': '1331',
'DOI': '10.1080/07391102.2020.1828172',
'article-title': 'Structural analysis, virtual screening and molecular simulation to '
"identify potential inhibitors targeting 2'-O-ribose methyltransferase "
'of SARS-CoV-2 coronavirus',
'volume': '40',
'author': 'Jiang',
'year': '2022',
'journal-title': 'J. Biomol. Struct. Dyn.'},
{ 'issue': '23',
'key': '10.1016/j.mcp.2024.101973_bib60',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/ma13235362',
'article-title': 'Characterization of structural and energetic differences between '
'conformations of the SARS-CoV-2 spike protein',
'volume': '13',
'author': 'Moreira',
'year': '2020',
'journal-title': 'Materials'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib61',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.ppat.1004077',
'article-title': 'Severe acute respiratory syndrome coronavirus envelope protein ion '
'channel activity promotes virus fitness and pathogenesis',
'volume': '10',
'author': 'Nieto-Torres',
'year': '2014',
'journal-title': 'PLoS Pathog.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib62',
'doi-asserted-by': 'crossref',
'first-page': '613',
'DOI': '10.1038/s41423-020-00571-x',
'article-title': 'SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate '
'antiviral response',
'volume': '18',
'author': 'Fu',
'year': '2021',
'journal-title': 'Cell. Mol. Immunol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib63',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jviromet.2019.113806',
'article-title': 'Analysis of preferred codon usage in the coronavirus N genes and their '
'implications for genome evolution and vaccine design',
'volume': '277',
'author': 'Sheikh',
'year': '2020',
'journal-title': 'J Virol Methods'},
{ 'issue': '7840',
'key': '10.1016/j.mcp.2024.101973_bib64',
'doi-asserted-by': 'crossref',
'first-page': '125',
'DOI': '10.1038/s41586-020-2739-1',
'article-title': 'The coding capacity of SARS-CoV-2',
'volume': '589',
'author': 'Finkel',
'year': '2021',
'journal-title': 'Nature'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib65',
'doi-asserted-by': 'crossref',
'first-page': '2642',
'DOI': '10.1038/s41467-021-22905-7',
'article-title': 'SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 '
'Sarbecovirus genomes',
'volume': '12',
'author': 'Jungreis',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib66',
'doi-asserted-by': 'crossref',
'first-page': '616',
'DOI': '10.1093/bib/bbaa297',
'article-title': 'Next generation sequencing of SARS-CoV-2 genomes: challenges, '
'applications and opportunities',
'volume': '22',
'author': 'Chiara',
'year': '2021',
'journal-title': 'Brief Bioinform'},
{ 'issue': '6548',
'key': '10.1016/j.mcp.2024.101973_bib67',
'doi-asserted-by': 'crossref',
'first-page': '1306',
'DOI': '10.1126/science.abf3546',
'article-title': 'Structural basis of ribosomal frameshifting during translation of the '
'SARS-CoV-2 RNA genome',
'volume': '372',
'author': 'Bhatt',
'year': '2021',
'journal-title': 'Science'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib68',
'doi-asserted-by': 'crossref',
'first-page': '177',
'DOI': '10.3390/v14071526',
'article-title': 'Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is '
'Insufficient to Impair Viral Replication in Vero Cells. Comment on '
'Munshi et al. Identifying Inhibitors of -1 Programmed Ribosomal '
'Frameshifting in a Broad Spectrum of Coronaviruses',
'volume': '14',
'author': 'Jager',
'year': '2022',
'journal-title': 'Viruses'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib69',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/v14020177',
'article-title': 'Identifying inhibitors of -1 programmed ribosomal frameshifting in a '
'broad spectrum of coronaviruses',
'volume': '14',
'author': 'Munshi',
'year': '2022',
'journal-title': 'Viruses'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib70',
'first-page': '11',
'article-title': 'The origin, transmission and clinical therapies on coronavirus disease '
'2019 (COVID-19) outbreak - an update on the status',
'volume': '7',
'author': 'Guo',
'year': '2020',
'journal-title': 'Mil Med Res'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib71',
'doi-asserted-by': 'crossref',
'first-page': '155',
'DOI': '10.1038/s41579-020-00468-6',
'article-title': 'Coronavirus biology and replication: implications for SARS-CoV-2',
'volume': '19',
'author': "V'Kovski",
'year': '2021',
'journal-title': 'Nat. Rev. Microbiol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib72',
'doi-asserted-by': 'crossref',
'DOI': '10.7554/eLife.42037',
'article-title': 'Determination of host proteins composing the microenvironment of '
'coronavirus replicase complexes by proximity-labeling',
'volume': '8',
'author': "V'Kovski",
'year': '2019',
'journal-title': 'Elife'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib73',
'doi-asserted-by': 'crossref',
'first-page': '3810',
'DOI': '10.1038/s41467-020-17665-9',
'article-title': 'Activation and evasion of type I interferon responses by SARS-CoV-2',
'volume': '11',
'author': 'Lei',
'year': '2020',
'journal-title': 'Nat. Commun.'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib74',
'doi-asserted-by': 'crossref',
'first-page': '914',
'DOI': '10.1016/j.cell.2020.04.011',
'article-title': 'The architecture of SARS-CoV-2 transcriptome',
'volume': '181',
'author': 'Kim',
'year': '2020',
'journal-title': 'Cell'},
{ 'key': '10.1016/j.mcp.2024.101973_bib75',
'series-title': 'Uncovering the Science of Covid-19',
'first-page': '233',
'article-title': 'Antagonism and evasion of cellular innate immunity by SARS-CoV-2',
'author': 'Swaraj',
'year': '2023'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib76',
'doi-asserted-by': 'crossref',
'first-page': '1247',
'DOI': '10.3390/v14061247',
'article-title': 'Characterization of SARS-CoV-2 evasion: interferon pathway and '
'therapeutic options',
'volume': '14',
'author': 'Znaidia',
'year': '2022',
'journal-title': 'Viruses'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib77',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.phyplu.2020.100002',
'article-title': "Nature's therapy for COVID-19: targeting the vital non-structural "
'proteins (NSP) from SARS-CoV-2 with phytochemicals from Indian '
'medicinal plants',
'volume': '1',
'author': 'Parida',
'year': '2021',
'journal-title': 'Phytomed Plus'},
{ 'issue': '6498',
'key': '10.1016/j.mcp.2024.101973_bib78',
'doi-asserted-by': 'crossref',
'first-page': '1499',
'DOI': '10.1126/science.abc1560',
'article-title': 'Structural basis for inhibition of the RNA-dependent RNA polymerase '
'from SARS-CoV-2 by remdesivir',
'volume': '368',
'author': 'Yin',
'year': '2020',
'journal-title': 'Science'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib79',
'doi-asserted-by': 'crossref',
'first-page': '853',
'DOI': '10.1016/j.chom.2020.11.003',
'article-title': 'Integrative imaging reveals SARS-CoV-2-induced reshaping of subcellular '
'morphologies',
'volume': '28',
'author': 'Cortese',
'year': '2020',
'journal-title': 'Cell Host Microbe'},
{ 'issue': '36',
'key': '10.1016/j.mcp.2024.101973_bib80',
'doi-asserted-by': 'crossref',
'first-page': '9904',
'DOI': '10.1039/D0SC02646H',
'article-title': 'Multi-targeting of functional cysteines in multiple conserved '
'SARS-CoV-2 domains by clinically safe Zn-ejectors',
'volume': '11',
'author': 'Sargsyan',
'year': '2020',
'journal-title': 'Chem. Sci.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib81',
'doi-asserted-by': 'crossref',
'first-page': '57',
'DOI': '10.1016/j.coviro.2019.04.002',
'article-title': 'Nucleoside analogues for the treatment of coronavirus infections',
'volume': '35',
'author': 'Pruijssers',
'year': '2019',
'journal-title': 'Curr Opin Virol'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib82',
'doi-asserted-by': 'crossref',
'first-page': '265',
'DOI': '10.1146/annurev-virology-100114-055218',
'article-title': 'Continuous and discontinuous RNA synthesis in coronaviruses',
'volume': '2',
'author': 'Sola',
'year': '2015',
'journal-title': 'Annu Rev Virol'},
{ 'issue': '6483',
'key': '10.1016/j.mcp.2024.101973_bib83',
'doi-asserted-by': 'crossref',
'first-page': '1260',
'DOI': '10.1126/science.abb2507',
'article-title': 'Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation',
'volume': '367',
'author': 'Wrapp',
'year': '2020',
'journal-title': 'Science'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib84',
'doi-asserted-by': 'crossref',
'first-page': '281',
'DOI': '10.1016/j.cell.2020.02.058',
'article-title': 'Structure, function, and antigenicity of the SARS-CoV-2 spike '
'glycoprotein',
'volume': '181',
'author': 'Walls',
'year': '2020',
'journal-title': 'Cell'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib85',
'doi-asserted-by': 'crossref',
'first-page': '3025',
'DOI': '10.1080/07391102.2020.1754293',
'article-title': 'A review on the cleavage priming of the spike protein on coronavirus by '
'angiotensin-converting enzyme-2 and furin',
'volume': '39',
'author': 'Hasan',
'year': '2021',
'journal-title': 'J. Biomol. Struct. Dyn.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib86',
'doi-asserted-by': 'crossref',
'first-page': '7193',
'DOI': '10.1038/s41467-021-27431-0',
'article-title': 'The short isoform of the host antiviral protein ZAP acts as an '
'inhibitor of SARS-CoV-2 programmed ribosomal frameshifting',
'volume': '12',
'author': 'Zimmer',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib87',
'doi-asserted-by': 'crossref',
'first-page': '1115',
'DOI': '10.3390/v13061115',
'article-title': 'The SARS-CoV-2 nucleocapsid protein and its role in viral structure, '
'biological functions, and a potential target for drug or vaccine '
'mitigation',
'volume': '13',
'author': 'Bai',
'year': '2021',
'journal-title': 'Viruses'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib88',
'doi-asserted-by': 'crossref',
'first-page': 'e00507',
'DOI': '10.1128/jvi.00507-23',
'article-title': 'The REEP5/TRAM1 complex binds SARS-CoV-2 NSP3 and promotes virus '
'replication',
'volume': '97',
'author': 'Li',
'year': '2023',
'journal-title': 'J. Virol.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib89',
'doi-asserted-by': 'crossref',
'first-page': 'eabm4034',
'DOI': '10.1126/sciadv.abm4034',
'article-title': 'The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic '
'complex with its viral partner nsp3a',
'volume': '8',
'author': 'Bessa',
'year': '2022',
'journal-title': 'Sci. Adv.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib90',
'doi-asserted-by': 'crossref',
'first-page': '2013',
'DOI': '10.1007/s00415-020-10197-8',
'article-title': 'Why do SARS-CoV-2 NSPs rush to the ER?',
'volume': '268',
'author': 'Santerre',
'year': '2021',
'journal-title': 'J. Neurol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib91',
'doi-asserted-by': 'crossref',
'first-page': '5885',
'DOI': '10.1038/s41467-020-19619-7',
'article-title': 'SARS-CoV-2 structure and replication characterized by in situ '
'cryo-electron tomography',
'volume': '11',
'author': 'Klein',
'year': '2020',
'journal-title': 'Nat. Commun.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib92',
'doi-asserted-by': 'crossref',
'first-page': '844',
'DOI': '10.1111/j.1462-5822.2010.01437.x',
'article-title': 'Qualitative and quantitative ultrastructural analysis of the membrane '
'rearrangements induced by coronavirus',
'volume': '12',
'author': 'Ulasli',
'year': '2010',
'journal-title': 'Cell Microbiol.'},
{ 'issue': '6509',
'key': '10.1016/j.mcp.2024.101973_bib93',
'doi-asserted-by': 'crossref',
'first-page': '1395',
'DOI': '10.1126/science.abd3629',
'article-title': 'A molecular pore spans the double membrane of the coronavirus '
'replication organelle',
'volume': '369',
'author': 'Wolff',
'year': '2020',
'journal-title': 'Science'},
{ 'issue': '22',
'key': '10.1016/j.mcp.2024.101973_bib94',
'doi-asserted-by': 'crossref',
'first-page': '11318',
'DOI': '10.1128/JVI.01052-08',
'article-title': 'The M, E, and N structural proteins of the severe acute respiratory '
'syndrome coronavirus are required for efficient assembly, trafficking, '
'and release of virus-like particles',
'volume': '82',
'author': 'Siu',
'year': '2008',
'journal-title': 'J. Virol.'},
{ 'issue': '12',
'key': '10.1016/j.mcp.2024.101973_bib95',
'doi-asserted-by': 'crossref',
'first-page': '6558',
'DOI': '10.3390/ijms22126558',
'article-title': 'Studying SARS-CoV-2 with fluorescence microscopy',
'volume': '22',
'author': 'Putlyaeva',
'year': '2021',
'journal-title': 'Int. J. Mol. Sci.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib96',
'series-title': 'COVID-19 and Perinatology',
'first-page': '49',
'article-title': 'Biological mechanisms of transplacental SARS-COV-2 transmission',
'author': 'Pirola',
'year': '2023'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib97',
'doi-asserted-by': 'crossref',
'first-page': '500',
'DOI': '10.1016/j.chom.2010.05.013',
'article-title': 'Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles '
'exporting short-lived ERAD regulators, for replication',
'volume': '7',
'author': 'Reggiori',
'year': '2010',
'journal-title': 'Cell Host Microbe'},
{ 'key': '10.1016/j.mcp.2024.101973_bib98',
'article-title': 'Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 '
'replication',
'author': 'Silvas',
'year': '2020',
'journal-title': 'bioRxiv'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib99',
'doi-asserted-by': 'crossref',
'first-page': '151',
'DOI': '10.1016/j.fmre.2021.01.013',
'article-title': 'Drug discovery and development targeting the life cycle of SARS-CoV-2',
'volume': '1',
'author': 'Su',
'year': '2021',
'journal-title': 'Fundamental Research'},
{ 'key': '10.1016/j.mcp.2024.101973_bib100',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.cellsig.2020.109721',
'article-title': 'Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring '
'promising drugs for the treatment of Covid-19',
'volume': '74',
'author': 'Poduri',
'year': '2020',
'journal-title': 'Cell. Signal.'},
{ 'issue': '16',
'key': '10.1016/j.mcp.2024.101973_bib101',
'doi-asserted-by': 'crossref',
'first-page': '9121',
'DOI': '10.1039/D0CS01065K',
'article-title': 'A critical overview of computational approaches employed for COVID-19 '
'drug discovery',
'volume': '50',
'author': 'Muratov',
'year': '2021',
'journal-title': 'Chem. Soc. Rev.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib102',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.antiviral.2020.104786',
'article-title': 'Remdesivir, lopinavir, emetine, and homoharringtonine inhibit '
'SARS-CoV-2 replication in vitro',
'volume': '178',
'author': 'Choy',
'year': '2020',
'journal-title': 'Antiviral Res'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib103',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ijantimicag.2020.106274',
'article-title': 'Inhibition of the replication of SARS-CoV-2 in human cells by the '
'FDA-approved drug chlorpromazine',
'volume': '57',
'author': 'Plaze',
'year': '2021',
'journal-title': 'Int. J. Antimicrob. Agents'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib104',
'doi-asserted-by': 'crossref',
'first-page': '593',
'DOI': '10.1038/s41579-019-0233-2',
'article-title': 'Therapeutic strategies to target the Ebola virus life cycle',
'volume': '17',
'author': 'Hoenen',
'year': '2019',
'journal-title': 'Nat. Rev. Microbiol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib105',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ejmech.2023.115503',
'article-title': 'Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in '
'China',
'volume': '257',
'author': 'Yang',
'year': '2023',
'journal-title': 'Eur. J. Med. Chem.'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib106',
'doi-asserted-by': 'crossref',
'first-page': '1519',
'DOI': '10.1002/med.21664',
'article-title': 'Medicinal chemistry strategies toward host targeting antiviral agents',
'volume': '40',
'author': 'Ji',
'year': '2020',
'journal-title': 'Med. Res. Rev.'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib107',
'doi-asserted-by': 'crossref',
'first-page': '678',
'DOI': '10.1038/s41422-020-0356-z',
'article-title': 'Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 '
'viral replication by targeting the viral main protease',
'volume': '30',
'author': 'Ma',
'year': '2020',
'journal-title': 'Cell Res.'},
{ 'issue': '21',
'key': '10.1016/j.mcp.2024.101973_bib108',
'doi-asserted-by': 'crossref',
'first-page': '12725',
'DOI': '10.1021/acs.jmedchem.0c01063',
'article-title': 'Discovery of ketone-based covalent inhibitors of coronavirus 3CL '
'proteases for the potential therapeutic treatment of COVID-19',
'volume': '63',
'author': 'Hoffman',
'year': '2020',
'journal-title': 'J. Med. Chem.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib109',
'doi-asserted-by': 'crossref',
'first-page': '96',
'DOI': '10.1093/cid/cir774',
'article-title': 'Boceprevir and telaprevir in the management of hepatitis C '
'virus–infected patients',
'volume': '54',
'author': 'Butt',
'year': '2012',
'journal-title': 'Clin. Infect. Dis.'},
{ 'issue': '6536',
'key': '10.1016/j.mcp.2024.101973_bib110',
'doi-asserted-by': 'crossref',
'first-page': '1374',
'DOI': '10.1126/science.abf1611',
'article-title': 'SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic '
'mouse model',
'volume': '371',
'author': 'Qiao',
'year': '2021',
'journal-title': 'Science'},
{ 'issue': '51',
'key': '10.1016/j.mcp.2024.101973_bib111',
'doi-asserted-by': 'crossref',
'first-page': 'eadd7197',
'DOI': '10.1126/sciadv.add7197',
'article-title': 'Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an '
'infectious cell culture system',
'volume': '8',
'author': 'Zhou',
'year': '2022',
'journal-title': 'Sci. Adv.'},
{ 'issue': '7944',
'key': '10.1016/j.mcp.2024.101973_bib112',
'doi-asserted-by': 'crossref',
'first-page': '558',
'DOI': '10.1038/s41586-022-05514-2',
'article-title': 'Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir',
'volume': '613',
'author': 'Iketani',
'year': '2023',
'journal-title': 'Nature'},
{ 'issue': '678',
'key': '10.1016/j.mcp.2024.101973_bib113',
'doi-asserted-by': 'crossref',
'first-page': 'eabq7360',
'DOI': '10.1126/scitranslmed.abq7360',
'article-title': 'SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer '
'resistance to nirmatrelvir, ensitrelvir, and GC376',
'volume': '15',
'author': 'Heilmann',
'year': '2022',
'journal-title': 'Sci. Transl. Med.'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib114',
'doi-asserted-by': 'crossref',
'first-page': '1636',
'DOI': '10.1016/j.apsb.2021.10.026',
'article-title': 'Validation and invalidation of SARS-CoV-2 main protease inhibitors '
'using the Flip-GFP and Protease-Glo luciferase assays',
'volume': '12',
'author': 'Ma',
'year': '2022',
'journal-title': 'Acta Pharm. Sin. B'},
{ 'issue': '15',
'key': '10.1016/j.mcp.2024.101973_bib115',
'doi-asserted-by': 'crossref',
'first-page': '6921',
'DOI': '10.1080/07391102.2021.1891969',
'article-title': 'Structure-based virtual screening, molecular dynamics and binding '
'affinity calculations of some potential phytocompounds against '
'SARS-CoV-2',
'volume': '40',
'author': 'Naik',
'year': '2022',
'journal-title': 'J. Biomol. Struct. Dyn.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib116',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/mBio.00221-18',
'article-title': 'Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is '
'mediated by the viral polymerase and the proofreading exoribonuclease',
'volume': '9',
'author': 'Agostini',
'year': '2018',
'journal-title': 'mBio'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib117',
'doi-asserted-by': 'crossref',
'first-page': '529',
'DOI': '10.1038/s41594-020-0440-6',
'article-title': 'Structural basis for the inhibition of SARS-CoV-2 main protease by '
'antineoplastic drug carmofur',
'volume': '27',
'author': 'Jin',
'year': '2020',
'journal-title': 'Nat. Struct. Mol. Biol.'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib118',
'doi-asserted-by': 'crossref',
'first-page': '1167',
'DOI': '10.1038/s41401-020-0483-6',
'article-title': 'Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and '
'bioactive ingredients',
'volume': '41',
'author': 'Su',
'year': '2020',
'journal-title': 'Acta Pharmacol. Sin.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib119',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ejmech.2023.115720',
'article-title': 'Discovery of antiviral SARS-CoV-2 main protease inhibitors by '
'structure-guided hit-to-lead optimization of carmofur',
'volume': '260',
'author': 'Kang',
'year': '2023',
'journal-title': 'Eur. J. Med. Chem.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib120',
'doi-asserted-by': 'crossref',
'first-page': '3061',
'DOI': '10.1038/s41467-021-23313-7',
'article-title': 'Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its '
'derivatives',
'volume': '12',
'author': 'Amporndanai',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib121',
'doi-asserted-by': 'crossref',
'first-page': '1265',
'DOI': '10.1021/acsptsci.0c00130',
'article-title': 'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are '
'nonspecific promiscuous SARS-CoV-2 main protease inhibitors',
'volume': '3',
'author': 'Ma',
'year': '2020',
'journal-title': 'ACS Pharmacol. Transl. Sci.'},
{ 'issue': '7811',
'key': '10.1016/j.mcp.2024.101973_bib122',
'doi-asserted-by': 'crossref',
'first-page': '289',
'DOI': '10.1038/s41586-020-2223-y',
'article-title': 'Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors',
'volume': '582',
'author': 'Jin',
'year': '2020',
'journal-title': 'Nature'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib123',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jbc.2023.103004',
'article-title': 'Structural basis of nirmatrelvir and ensitrelvir activity against '
'naturally occurring polymorphisms of the SARS-CoV-2 main protease',
'volume': '299',
'author': 'Noske',
'year': '2023',
'journal-title': 'J. Biol. Chem.'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib124',
'doi-asserted-by': 'crossref',
'first-page': '354',
'DOI': '10.1007/s00894-022-05341-2',
'article-title': 'Reactivity and binding mode of disulfiram, its metabolites, and '
'derivatives in SARS-CoV-2 PLpro: insights from computational chemistry '
'studies',
'volume': '28',
'author': 'Nogara',
'year': '2022',
'journal-title': 'J. Mol. Model.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib125',
'doi-asserted-by': 'crossref',
'first-page': '497',
'DOI': '10.1080/14756366.2021.1873977',
'article-title': 'Scutellaria baicalensis extract and baicalein inhibit replication of '
'SARS-CoV-2 and its 3C-like protease in vitro',
'volume': '36',
'author': 'Liu',
'year': '2021',
'journal-title': 'J. Enzym. Inhib. Med. Chem.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib126',
'doi-asserted-by': 'crossref',
'first-page': '122',
'DOI': '10.1159/000519564',
'article-title': 'Study of baicalin toward COVID-19 Treatment: in silico target analysis '
'and in vitro inhibitory effects on SARS-CoV-2 proteases',
'volume': '6',
'author': 'Lin',
'year': '2021',
'journal-title': 'Biomed. Hub'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib127',
'doi-asserted-by': 'crossref',
'first-page': '4562',
'DOI': '10.1021/acs.jmedchem.9b01828',
'article-title': 'α-Ketoamides as broad-spectrum inhibitors of coronavirus and '
'enterovirus replication: structure-based design, synthesis, and '
'activity assessment',
'volume': '63',
'author': 'Zhang',
'year': '2020',
'journal-title': 'J. Med. Chem.'},
{ 'issue': '6489',
'key': '10.1016/j.mcp.2024.101973_bib128',
'doi-asserted-by': 'crossref',
'first-page': '409',
'DOI': '10.1126/science.abb3405',
'article-title': 'Crystal structure of SARS-CoV-2 main protease provides a basis for '
'design of improved α-ketoamide inhibitors',
'volume': '368',
'author': 'Zhang',
'year': '2020',
'journal-title': 'Science'},
{ 'issue': '13',
'key': '10.1016/j.mcp.2024.101973_bib129',
'doi-asserted-by': 'crossref',
'first-page': 'eade8778',
'DOI': '10.1126/sciadv.ade8778',
'article-title': 'Transmissible SARS-CoV-2 variants with resistance to clinical protease '
'inhibitors',
'volume': '9',
'author': 'Moghadasi',
'year': '2023',
'journal-title': 'Sci. Adv.'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib130',
'doi-asserted-by': 'crossref',
'DOI': '10.1097/MD.0000000000033024',
'article-title': 'A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection '
'(Phase 3 part)',
'volume': '102',
'author': 'Yotsuyanagi',
'year': '2023',
'journal-title': 'Medicine'},
{ 'key': '10.1016/j.mcp.2024.101973_bib131',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jiac.2024.02.015',
'article-title': 'Ensitrelvir in patients with SARS-CoV-2: a retrospective chart review',
'author': 'Yamato',
'year': '2024',
'journal-title': 'J. Infect. Chemother.'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib132',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pone.0267471',
'article-title': 'Computational prediction of potential inhibitors for SARS-COV-2 main '
'protease based on machine learning, docking, MM-PBSA calculations, and '
'metadynamics',
'volume': '17',
'author': 'Gomes',
'year': '2022',
'journal-title': 'PLoS One'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib133',
'doi-asserted-by': 'crossref',
'first-page': '1245',
'DOI': '10.1021/acscentsci.1c00519',
'article-title': 'Discovery of SARS-CoV-2 papain-like protease inhibitors through a '
'combination of high-throughput screening and a FlipGFP-based reporter '
'assay',
'volume': '7',
'author': 'Ma',
'year': '2021',
'journal-title': 'ACS Cent. Sci.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib134',
'doi-asserted-by': 'crossref',
'first-page': '102',
'DOI': '10.1021/acsptsci.1c00240',
'article-title': 'Validation and invalidation of SARS-CoV-2 papain-like protease '
'inhibitors',
'volume': '5',
'author': 'Ma',
'year': '2022',
'journal-title': 'ACS Pharmacol. Transl. Sci.'},
{ 'issue': '22',
'key': '10.1016/j.mcp.2024.101973_bib135',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/JVI.01265-20',
'article-title': 'Development of a fluorescence-based, high-throughput SARS-CoV-2 '
'3CL(pro) reporter assay',
'volume': '94',
'author': 'Froggatt',
'year': '2020',
'journal-title': 'J. Virol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib136',
'article-title': 'Design of SARS-CoV-2 papain-like protease inhibitor with antiviral '
'efficacy in a mouse model',
'author': 'Tan',
'year': '2023',
'journal-title': 'bioRxiv'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib137',
'doi-asserted-by': 'crossref',
'first-page': '2367',
'DOI': '10.1016/j.drudis.2021.05.008',
'article-title': 'Drug combination therapy for emerging viral diseases',
'volume': '26',
'author': 'Shyr',
'year': '2021',
'journal-title': 'Drug Discov. Today'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib138',
'doi-asserted-by': 'crossref',
'first-page': '2099',
'DOI': '10.1021/acsinfecdis.0c00168',
'article-title': 'Characterization and noncovalent inhibition of the deubiquitinase and '
'deISGylase activity of SARS-CoV-2 papain-like protease',
'volume': '6',
'author': 'Freitas',
'year': '2020',
'journal-title': 'ACS Infect. Dis.'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib139',
'doi-asserted-by': 'crossref',
'first-page': '7561',
'DOI': '10.1021/acs.jmedchem.2c00303',
'article-title': 'Progress and challenges in targeting the SARS-CoV-2 papain-like '
'protease',
'volume': '65',
'author': 'Tan',
'year': '2022',
'journal-title': 'J. Med. Chem.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib140',
'doi-asserted-by': 'crossref',
'DOI': '10.1038/d41591-020-00019-9',
'article-title': '15 drugs being tested to treat COVID-19 and how they would work',
'author': 'Shaffer',
'year': '2020',
'journal-title': 'Nat Med'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib141',
'doi-asserted-by': 'crossref',
'first-page': '879',
'DOI': '10.1136/gutjnl-2022-326952',
'article-title': 'Oral famotidine versus placebo in non-hospitalised patients with '
'COVID-19: a randomised, double-blind, data-intense, phase 2 clinical '
'trial',
'volume': '71',
'author': 'Brennan',
'year': '2022',
'journal-title': 'Gut'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib142',
'doi-asserted-by': 'crossref',
'first-page': '766',
'DOI': '10.1016/j.apsb.2020.02.008',
'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of '
'potential drugs by computational methods',
'volume': '10',
'author': 'Wu',
'year': '2020',
'journal-title': 'Acta Pharm. Sin. B'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib143',
'doi-asserted-by': 'crossref',
'first-page': '5433',
'DOI': '10.1038/s41598-021-84782-w',
'article-title': 'The in-vitro effect of famotidine on sars-cov-2 proteases and virus '
'replication',
'volume': '11',
'author': 'Loffredo',
'year': '2021',
'journal-title': 'Sci. Rep.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib144',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jbc.2021.100925',
'article-title': 'Famotidine inhibits toll-like receptor 3-mediated inflammatory '
'signaling in SARS-CoV-2 infection',
'volume': '297',
'author': 'Mukherjee',
'year': '2021',
'journal-title': 'J. Biol. Chem.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib145',
'first-page': '2020',
'article-title': 'Ebselen as a highly active inhibitor of PLProCoV2',
'author': 'Ewelina',
'year': '2020',
'journal-title': 'bioRxiv'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib146',
'doi-asserted-by': 'crossref',
'first-page': '3640',
'DOI': '10.1038/s41598-021-83229-6',
'article-title': 'Identification of ebselen and its analogues as potent covalent '
'inhibitors of papain-like protease from SARS-CoV-2',
'volume': '11',
'author': 'Weglarz-Tomczak',
'year': '2021',
'journal-title': 'Sci. Rep.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib147',
'doi-asserted-by': 'crossref',
'first-page': '488',
'DOI': '10.1038/s41467-020-20718-8',
'article-title': 'The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot '
'spot for antiviral drug discovery',
'volume': '12',
'author': 'Fu',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '42',
'key': '10.1016/j.mcp.2024.101973_bib148',
'doi-asserted-by': 'crossref',
'first-page': '16119',
'DOI': '10.1073/pnas.0805240105',
'article-title': 'A noncovalent class of papain-like protease/deubiquitinase inhibitors '
'blocks SARS virus replication',
'volume': '105',
'author': 'Ratia',
'year': '2008',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib149',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/ijms24108633',
'article-title': 'Structure-based design of potent peptidomimetic inhibitors covalently '
'targeting SARS-CoV-2 papain-like protease',
'volume': '24',
'author': 'Wang',
'year': '2023',
'journal-title': 'Int. J. Mol. Sci.'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib150',
'doi-asserted-by': 'crossref',
'first-page': '3976',
'DOI': '10.1111/cas.14618',
'article-title': 'RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for '
'cancer and potentially COVID-19',
'volume': '111',
'author': 'Machitani',
'year': '2020',
'journal-title': 'Cancer Sci.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib151',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/aac.00222-22',
'article-title': 'Remdesivir and GS-441524 retain antiviral activity against delta, '
'Omicron, and other emergent SARS-CoV-2 variants',
'volume': '66',
'author': 'Pitts',
'year': '2022',
'journal-title': 'Antimicrob. Agents Chemother.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib152',
'doi-asserted-by': 'crossref',
'first-page': '269',
'DOI': '10.1038/s41422-020-0282-0',
'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged '
'novel coronavirus (2019-nCoV) in vitro',
'volume': '30',
'author': 'Wang',
'year': '2020',
'journal-title': 'Cell Res.'},
{ 'issue': '396',
'key': '10.1016/j.mcp.2024.101973_bib153',
'doi-asserted-by': 'crossref',
'DOI': '10.1126/scitranslmed.aal3653',
'article-title': 'Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic '
'coronaviruses',
'volume': '9',
'author': 'Sheahan',
'year': '2017',
'journal-title': 'Sci. Transl. Med.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib154',
'article-title': 'Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir',
'volume': '2',
'author': 'Peng',
'year': '2021',
'journal-title': 'Innovation'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib155',
'doi-asserted-by': 'crossref',
'DOI': '10.1002/prp2.909',
'article-title': 'Molnupiravir: a new candidate for COVID-19 treatment',
'volume': '10',
'author': 'Pourkarim',
'year': '2022',
'journal-title': 'Pharmacol Res Perspect'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib156',
'doi-asserted-by': 'crossref',
'first-page': '109',
'DOI': '10.1016/0035-9203(58)90032-4',
'article-title': 'Chemotherapy of onchocerciasis',
'volume': '52',
'author': 'Hawking',
'year': '1958',
'journal-title': 'Trans. R. Soc. Trop. Med. Hyg.'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib157',
'first-page': 'e62',
'article-title': 'The approved pediatric drug suramin identified as a clinical candidate '
'for the treatment of EV71 infection-suramin inhibits EV71 infection in '
'vitro and in vivo',
'volume': '3',
'author': 'Ren',
'year': '2014',
'journal-title': 'Emerg Microbes Infect'},
{ 'key': '10.1016/j.mcp.2024.101973_bib158',
'doi-asserted-by': 'crossref',
'first-page': '23',
'DOI': '10.4103/2277-9175.201682',
'article-title': 'Simple and easy to perform preimplantation genetic diagnosis for '
'beta-thalassemia major using combination of conventional and '
'fluorescent polymerase chain reaction',
'volume': '6',
'author': 'Salehi',
'year': '2017',
'journal-title': 'Adv. Biomed. Res.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib159',
'doi-asserted-by': 'crossref',
'first-page': '39',
'DOI': '10.1016/j.antiviral.2015.06.013',
'article-title': 'Suramin inhibits chikungunya virus replication through multiple '
'mechanisms',
'volume': '121',
'author': 'Albulescu',
'year': '2015',
'journal-title': 'Antiviral Res'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib160',
'doi-asserted-by': 'crossref',
'first-page': '149',
'DOI': '10.1186/s12985-016-0607-2',
'article-title': 'Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry',
'volume': '13',
'author': 'Henß',
'year': '2016',
'journal-title': 'Virol. J.'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib161',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/AAC.00900-20',
'article-title': 'Suramin inhibits SARS-CoV-2 infection in cell culture by interfering '
'with early steps of the replication cycle',
'volume': '64',
'author': 'Salgado-Benvindo',
'year': '2020',
'journal-title': 'Antimicrob. Agents Chemother.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib162',
'doi-asserted-by': 'crossref',
'first-page': '319',
'DOI': '10.1038/s41594-021-00570-0',
'article-title': 'Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by '
'suramin',
'volume': '28',
'author': 'Yin',
'year': '2021',
'journal-title': 'Nat. Struct. Mol. Biol.'},
{ 'issue': '7',
'key': '10.1016/j.mcp.2024.101973_bib163',
'doi-asserted-by': 'crossref',
'first-page': '1548',
'DOI': '10.1016/j.molcel.2021.01.035',
'article-title': 'Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 '
'replication',
'volume': '81',
'author': 'Bravo',
'year': '2021',
'journal-title': 'Mol Cell'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib164',
'doi-asserted-by': 'crossref',
'first-page': '864',
'DOI': '10.1099/jmm.0.001203',
'article-title': 'Potential RNA-dependent RNA polymerase inhibitors as prospective '
'therapeutics against SARS-CoV-2',
'volume': '69',
'author': 'Pokhrel',
'year': '2020',
'journal-title': 'J. Med. Microbiol.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib165',
'doi-asserted-by': 'crossref',
'first-page': '483',
'DOI': '10.1038/s41401-021-00668-7',
'article-title': 'A multi-targeting drug design strategy for identifying potent '
'anti-SARS-CoV-2 inhibitors',
'volume': '43',
'author': 'Ren',
'year': '2022',
'journal-title': 'Acta Pharmacol. Sin.'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib166',
'doi-asserted-by': 'crossref',
'first-page': '542',
'DOI': '10.1016/j.gendis.2020.04.002',
'article-title': 'Genomics functional analysis and drug screening of SARS-CoV-2',
'volume': '7',
'author': 'Chen',
'year': '2020',
'journal-title': 'Genes Dis'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib167',
'doi-asserted-by': 'crossref',
'first-page': '43',
'DOI': '10.1186/s13045-019-0733-6',
'article-title': 'Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: '
'where we stand',
'volume': '12',
'author': 'Mei',
'year': '2019',
'journal-title': 'J. Hematol. Oncol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib168',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.celrep.2021.108940',
'article-title': 'Antiviral drug screen identifies DNA-damage response inhibitor as '
'potent blocker of SARS-CoV-2 replication',
'volume': '35',
'author': 'Garcia',
'year': '2021',
'journal-title': 'Cell Rep.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib169',
'doi-asserted-by': 'crossref',
'DOI': '10.1183/13993003.01919-2020',
'article-title': 'JAK inhibitors in COVID-19: the need for vigilance regarding increased '
'inherent thrombotic risk',
'volume': '56',
'author': 'Mehta',
'year': '2020',
'journal-title': 'Eur. Respir. J.'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib170',
'doi-asserted-by': 'crossref',
'DOI': '10.1126/sciadv.abi6110',
'article-title': 'Cannabidiol inhibits SARS-CoV-2 replication through induction of the '
'host ER stress and innate immune responses',
'volume': '8',
'author': 'Nguyen',
'year': '2022',
'journal-title': 'Sci. Adv.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib171',
'article-title': 'Corrigendum: interferon-alpha2b treatment for COVID-19',
'volume': '11',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Front. Immunol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib172',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.taap.2019.114713',
'article-title': 'Cannabidiol differentially regulates basal and LPS-induced inflammatory '
'responses in macrophages, lung epithelial cells, and fibroblasts',
'volume': '382',
'author': 'Muthumalage',
'year': '2019',
'journal-title': 'Toxicol. Appl. Pharmacol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib173',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fimmu.2022.870787',
'article-title': 'Cannabidiol and SARS-CoV-2 infection',
'volume': '13',
'author': 'Vallee',
'year': '2022',
'journal-title': 'Front. Immunol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib174',
'first-page': '726',
'volume': 'vol. 2766',
'author': 'Ndoutoume',
'year': '2022'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib175',
'doi-asserted-by': 'crossref',
'first-page': '271',
'DOI': '10.3390/v13020271',
'article-title': 'Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture',
'volume': '13',
'author': 'Bakovic',
'year': '2021',
'journal-title': 'Viruses'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib176',
'first-page': '1',
'article-title': 'Brilacidin, a non-peptide defensin-mimetic molecule, inhibits '
'SARS-CoV-2 infection by blocking viral entry',
'volume': '18',
'author': 'Xu',
'year': '2022',
'journal-title': 'EC Microbiol'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib177',
'doi-asserted-by': 'crossref',
'first-page': '2188',
'DOI': '10.1002/jmv.27616',
'article-title': 'Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum '
'antiviral activity against human coronaviruses OC43, 229E, and NL63 '
'through targeting both the virus and the host cell',
'volume': '94',
'author': 'Hu',
'year': '2022',
'journal-title': 'J. Med. Virol.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib178',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/microorganisms11030717',
'article-title': 'Identification of Z-tyr-ala-CHN(2), a cathepsin L inhibitor with '
'broad-spectrum cell-specific activity against coronaviruses, including '
'SARS-CoV-2',
'volume': '11',
'author': 'Doijen',
'year': '2023',
'journal-title': 'Microorganisms'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib179',
'doi-asserted-by': 'crossref',
'first-page': '2581',
'DOI': '10.1007/s13346-022-01146-1',
'article-title': 'Role of drug delivery technologies in the success of COVID-19 vaccines: '
'a perspective',
'volume': '12',
'author': 'Labouta',
'year': '2022',
'journal-title': 'Drug Deliv Transl Res'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib180',
'doi-asserted-by': 'crossref',
'first-page': '25',
'DOI': '10.1016/S0092-8674(00)80620-0',
'article-title': 'RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at '
'21 to 23 nucleotide intervals',
'volume': '101',
'author': 'Zamore',
'year': '2000',
'journal-title': 'Cell'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib181',
'doi-asserted-by': 'crossref',
'first-page': 'e96',
'DOI': '10.1038/mtna.2013.22',
'article-title': 'Efficient biodistribution and gene silencing in the lung epithelium via '
'intravenous liposomal delivery of siRNA',
'volume': '2',
'author': 'McCaskill',
'year': '2013',
'journal-title': 'Mol. Ther. Nucleic Acids'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib182',
'doi-asserted-by': 'crossref',
'first-page': '333',
'DOI': '10.1093/nar/gkab1248',
'article-title': 'Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient '
'inhibition of viral replication and spread',
'volume': '50',
'author': 'Ambike',
'year': '2022',
'journal-title': 'Nucleic Acids Res.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib183',
'doi-asserted-by': 'crossref',
'first-page': '661',
'DOI': '10.1016/j.jconrel.2022.03.051',
'article-title': 'Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER '
'polyplexes',
'volume': '345',
'author': 'Baldassi',
'year': '2022',
'journal-title': 'J Control Release'},
{ 'issue': '9',
'key': '10.1016/j.mcp.2024.101973_bib184',
'doi-asserted-by': 'crossref',
'first-page': '1602',
'DOI': '10.3390/nano12091602',
'article-title': 'Nanoparticles for coronavirus control',
'volume': '12',
'author': 'Kianpour',
'year': '2022',
'journal-title': 'Nanomaterials'},
{ 'key': '10.1016/j.mcp.2024.101973_bib185',
'article-title': 'Potency, safety, and pharmacokinetic profiles of potential inhibitors '
'targeting SARS-CoV-2 main protease',
'volume': '11',
'author': 'Mengist',
'year': '2020',
'journal-title': 'Front. Pharmacol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib186',
'doi-asserted-by': 'crossref',
'first-page': '4417',
'DOI': '10.1038/s41467-020-18233-x',
'article-title': 'Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting '
'its main protease',
'volume': '11',
'author': 'Fu',
'year': '2020',
'journal-title': 'Nat. Commun.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib187',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ejmech.2022.114596',
'article-title': 'A systematic exploration of boceprevir-based main protease inhibitors '
'as SARS-CoV-2 antivirals',
'volume': '240',
'author': 'Alugubelli',
'year': '2022',
'journal-title': 'Eur. J. Med. Chem.'},
{ 'issue': '6575',
'key': '10.1016/j.mcp.2024.101973_bib188',
'doi-asserted-by': 'crossref',
'first-page': '1586',
'DOI': '10.1126/science.abl4784',
'article-title': 'An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the '
'treatment of COVID-19',
'volume': '374',
'author': 'Owen',
'year': '2021',
'journal-title': 'Science'},
{ 'key': '10.1016/j.mcp.2024.101973_bib189',
'article-title': 'Discovery of a novel inhibitor of coronavirus 3CL protease for the '
'potential treatment of COVID-19',
'author': 'Boras',
'year': '2021',
'journal-title': 'bioRxiv'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib190',
'doi-asserted-by': 'crossref',
'first-page': '6055',
'DOI': '10.1038/s41467-021-26239-2',
'article-title': 'Preclinical characterization of an intravenous coronavirus 3CL protease '
'inhibitor for the potential treatment of COVID19',
'volume': '12',
'author': 'Boras',
'year': '2021',
'journal-title': 'Nat. Commun.'},
{ 'issue': '19',
'key': '10.1016/j.mcp.2024.101973_bib191',
'doi-asserted-by': 'crossref',
'first-page': '1787',
'DOI': '10.1056/NEJMoa2001282',
'article-title': 'A trial of lopinavir-ritonavir in adults hospitalized with severe '
'covid-19',
'volume': '382',
'author': 'Cao',
'year': '2020',
'journal-title': 'N. Engl. J. Med.'},
{ 'issue': '10259',
'key': '10.1016/j.mcp.2024.101973_bib192',
'doi-asserted-by': 'crossref',
'first-page': '1345',
'DOI': '10.1016/S0140-6736(20)32013-4',
'article-title': 'Lopinavir-ritonavir in patients admitted to hospital with COVID-19 '
'(RECOVERY): a randomised, controlled, open-label, platform trial',
'volume': '396',
'author': 'Group',
'year': '2020',
'journal-title': 'Lancet'},
{ 'issue': '29',
'key': '10.1016/j.mcp.2024.101973_bib193',
'doi-asserted-by': 'crossref',
'DOI': '10.1073/pnas.2101555118',
'article-title': 'Postinfection treatment with a protease inhibitor increases survival of '
'mice with a fatal SARS-CoV-2 infection',
'volume': '118',
'author': 'Dampalla',
'year': '2021',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib194',
'doi-asserted-by': 'crossref',
'first-page': '481',
'DOI': '10.1080/22221751.2021.1899770',
'article-title': 'The preclinical inhibitor GS441524 in combination with GC376 '
'efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse '
'respiratory tract',
'volume': '10',
'author': 'Shi',
'year': '2021',
'journal-title': 'Emerg Microbes Infect'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib195',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pone.0259061',
'article-title': 'Disulfiram use is associated with lower risk of COVID-19: a '
'retrospective cohort study',
'volume': '16',
'author': 'Fillmore',
'year': '2021',
'journal-title': 'PLoS One'},
{ 'key': '10.1016/j.mcp.2024.101973_bib196',
'article-title': 'Safety and effeicacy of Disulfiram in Hospitalized patients with '
'moderate COVID-19: a randomized, double-blinded, placebo-controlled '
'trial',
'author': 'Mota',
'year': '2023',
'journal-title': 'medRxiv'},
{ 'key': '10.1016/j.mcp.2024.101973_bib197',
'article-title': 'Pharmacological effects of baicalin in lung diseases',
'volume': '14',
'author': 'Wang',
'year': '2023',
'journal-title': 'Front. Pharmacol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib198',
'doi-asserted-by': 'crossref',
'first-page': '1891',
'DOI': '10.1038/s41467-022-29413-2',
'article-title': 'Development of optimized drug-like small molecule inhibitors of the '
'SARS-CoV-2 3CL protease for treatment of COVID-19',
'volume': '13',
'author': 'Liu',
'year': '2022',
'journal-title': 'Nat. Commun.'},
{ 'issue': '8',
'key': '10.1016/j.mcp.2024.101973_bib199',
'doi-asserted-by': 'crossref',
'first-page': '1250',
'DOI': '10.3390/microorganisms8081250',
'article-title': 'Progress in developing inhibitors of SARS-CoV-2 3C-like protease',
'volume': '8',
'author': 'Li',
'year': '2020',
'journal-title': 'Microorganisms'},
{ 'key': '10.1016/j.mcp.2024.101973_bib200',
'doi-asserted-by': 'crossref',
'first-page': '53',
'DOI': '10.1016/j.ijsu.2020.10.018',
'article-title': 'Ebselen, a new candidate therapeutic against SARS-CoV-2',
'volume': '84',
'author': 'Haritha',
'year': '2020',
'journal-title': 'Int. J. Surg.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib201',
'doi-asserted-by': 'crossref',
'first-page': '297',
'DOI': '10.2147/IJGM.S446335',
'article-title': 'The efficacy and safety of nirmatrelvir/ritonavir against COVID-19 in '
'elderly patients',
'author': 'Xiang',
'year': '2024',
'journal-title': 'Int. J. Gen. Med.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib202',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fphar.2023.1067408',
'article-title': 'In vitro metabolic characterization of the SARS-CoV-2 papain-like '
'protease inhibitors GRL0617 and HY-17542',
'volume': '14',
'author': 'Cho',
'year': '2023',
'journal-title': 'Front. Pharmacol.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib203',
'article-title': 'Efficacy and safety of favipiravir in treating COVID-19 patients: a '
'meta-analysis of randomized control trials',
'volume': '15',
'author': 'Batool',
'year': '2023',
'journal-title': 'Cureus'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib204',
'doi-asserted-by': 'crossref',
'first-page': '415',
'DOI': '10.1016/S2213-2600(22)00412-X',
'article-title': 'Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a '
'multicentre, open-label, phase 3, randomised controlled trial of early '
'intervention versus standard care',
'volume': '11',
'author': 'Shah',
'year': '2023',
'journal-title': 'Lancet Respir. Med.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib205',
'doi-asserted-by': 'crossref',
'first-page': '89',
'DOI': '10.1186/s12879-023-08835-3',
'article-title': 'Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): '
'an open-label, randomised, controlled, adaptive platform trial',
'volume': '24',
'author': 'Luvira',
'year': '2024',
'journal-title': 'BMC Infect. Dis.'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib206',
'doi-asserted-by': 'crossref',
'first-page': '509',
'DOI': '10.1056/NEJMoa2116044',
'article-title': 'Molnupiravir for oral treatment of covid-19 in nonhospitalized patients',
'volume': '386',
'author': 'Jayk Bernal',
'year': '2022',
'journal-title': 'N. Engl. J. Med.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib207',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ijantimicag.2023.106870',
'article-title': 'Efficacy and safety of molnupiravir treatment for COVID-19: a '
'systematic review and meta-analysis of randomized controlled trials',
'volume': '62',
'author': 'Tian',
'year': '2023',
'journal-title': 'Int. J. Antimicrob. Agents'},
{ 'issue': '4',
'key': '10.1016/j.mcp.2024.101973_bib208',
'doi-asserted-by': 'crossref',
'first-page': '1665',
'DOI': '10.1007/s11845-022-03139-y',
'article-title': 'Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic '
'review',
'volume': '192',
'author': 'Mali',
'year': '2023',
'journal-title': 'Ir. J. Med. Sci.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib209',
'doi-asserted-by': 'crossref',
'first-page': '2051',
'DOI': '10.2147/DDDT.S416325',
'article-title': 'Phase I, single-dose study to assess the pharmacokinetics and safety of '
'suramin in healthy Chinese volunteers',
'volume': '17',
'author': 'Wu',
'year': '2023',
'journal-title': 'Drug Des Devel Ther'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib210',
'doi-asserted-by': 'crossref',
'first-page': '387',
'DOI': '10.1021/acsptsci.2c00045',
'article-title': "Different aspects of emetine's capabilities as a highly potent "
'SARS-CoV-2 inhibitor against COVID-19',
'volume': '5',
'author': 'Valipour',
'year': '2022',
'journal-title': 'ACS Pharmacol. Transl. Sci.'},
{ 'issue': '18',
'key': '10.1016/j.mcp.2024.101973_bib211',
'doi-asserted-by': 'crossref',
'first-page': '3603',
'DOI': '10.1158/1078-0432.CCR-23-0536',
'article-title': 'Targeting replication stress and chemotherapy resistance with a '
'combination of sacituzumab govitecan and berzosertib: a phase I '
'clinical trial',
'volume': '29',
'author': 'Abel',
'year': '2023',
'journal-title': 'Clin. Cancer Res.'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib212',
'doi-asserted-by': 'crossref',
'first-page': '658',
'DOI': '10.1089/can.2021.0093',
'article-title': 'Cannabidiol for COVID-19 patients with mild to moderate symptoms '
'(candidate study): a randomized, double-blind, placebo-controlled '
'clinical trial',
'volume': '7',
'author': 'Crippa',
'year': '2022',
'journal-title': 'Cannabis Cannabinoid Res'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib213',
'doi-asserted-by': 'crossref',
'first-page': '487',
'DOI': '10.1089/can.2021.0135',
'article-title': 'Cannabidiol as a treatment for COVID-19 symptoms? A critical review',
'volume': '8',
'author': 'Holst',
'year': '2023',
'journal-title': 'Cannabis Cannabinoid Res'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib214',
'doi-asserted-by': 'crossref',
'first-page': '136',
'DOI': '10.1186/s13578-021-00643-z',
'article-title': 'SARS-CoV-2: from its discovery to genome structure, transcription, and '
'replication',
'volume': '11',
'author': 'Brant',
'year': '2021',
'journal-title': 'Cell Biosci.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib215',
'doi-asserted-by': 'crossref',
'first-page': '17',
'DOI': '10.1093/infdis/jiaa185',
'article-title': 'Epidemiology of seasonal coronaviruses: establishing the context for '
'the emergence of coronavirus disease 2019',
'volume': '222',
'author': 'Nickbakhsh',
'year': '2020',
'journal-title': 'J. Infect. Dis.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib216',
'doi-asserted-by': 'crossref',
'first-page': '21',
'DOI': '10.1038/s41580-021-00432-z',
'article-title': 'Structures and functions of coronavirus replication-transcription '
'complexes and their relevance for SARS-CoV-2 drug design',
'volume': '23',
'author': 'Malone',
'year': '2022',
'journal-title': 'Nat. Rev. Mol. Cell Biol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib217',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ejmech.2021.113294',
'article-title': 'Protease targeted COVID-19 drug discovery: what we have learned from '
'the past SARS-CoV inhibitors?',
'volume': '215',
'author': 'Amin',
'year': '2021',
'journal-title': 'Eur. J. Med. Chem.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib218',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.bmc.2020.115860',
'article-title': 'Protease targeted COVID-19 drug discovery and its challenges: insight '
'into viral main protease (Mpro) and papain-like protease (PLpro) '
'inhibitors',
'volume': '29',
'author': 'Amin',
'year': '2021',
'journal-title': 'Bioorg. Med. Chem.'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib219',
'doi-asserted-by': 'crossref',
'first-page': '327',
'DOI': '10.2174/1389202916666150707160613',
'article-title': 'RNA viruses: RNA roles in pathogenesis, coreplication and viral load',
'volume': '16',
'author': 'Poltronieri',
'year': '2015',
'journal-title': 'Curr Genomics'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib220',
'doi-asserted-by': 'crossref',
'first-page': '857',
'DOI': '10.1080/1062936X.2020.1825014',
'article-title': 'Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for '
'the management of novel coronavirus 2019-nCoV',
'volume': '31',
'author': 'Singh',
'year': '2020',
'journal-title': 'SAR QSAR Environ. Res.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib221',
'doi-asserted-by': 'crossref',
'first-page': '226',
'DOI': '10.1038/nrmicro2090',
'article-title': 'The spike protein of SARS-CoV--a target for vaccine and therapeutic '
'development',
'volume': '7',
'author': 'Du',
'year': '2009',
'journal-title': 'Nat. Rev. Microbiol.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib222',
'doi-asserted-by': 'crossref',
'first-page': '120',
'DOI': '10.1016/j.virusres.2014.11.021',
'article-title': 'Host cell proteases: critical determinants of coronavirus tropism and '
'pathogenesis',
'volume': '202',
'author': 'Millet',
'year': '2015',
'journal-title': 'Virus Res.'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib224',
'doi-asserted-by': 'crossref',
'first-page': '270',
'DOI': '10.1038/s41579-022-00713-0',
'article-title': 'SARS-CoV-2 pathogenesis',
'volume': '20',
'author': 'Lamers',
'year': '2022',
'journal-title': 'Nat. Rev. Microbiol.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib225',
'doi-asserted-by': 'crossref',
'first-page': '935',
'DOI': '10.1021/acs.jmedchem.1c00302',
'article-title': 'Kinase inhibitors as underexplored antiviral agents',
'volume': '65',
'author': 'García-Cárceles',
'year': '2022',
'journal-title': 'J. Med. Chem.'},
{ 'issue': '3',
'key': '10.1016/j.mcp.2024.101973_bib226',
'doi-asserted-by': 'crossref',
'first-page': '323',
'DOI': '10.1002/wsbm.147',
'article-title': 'Drug repurposing and adverse event prediction using high-throughput '
'literature analysis',
'volume': '3',
'author': 'Deftereos',
'year': '2011',
'journal-title': 'Wiley Interdiscip Rev Syst Biol Med'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib227',
'doi-asserted-by': 'crossref',
'first-page': '95',
'DOI': '10.1186/s40001-023-01048-z',
'article-title': 'Pharmacovigilance-based drug repurposing: searching for putative drugs '
'with hypohidrosis or anhidrosis adverse events for use against '
'hyperhidrosis',
'volume': '28',
'author': 'Liu',
'year': '2023',
'journal-title': 'Eur. J. Med. Res.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib228',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fcell.2023.1238027',
'article-title': 'Current state-of-the-art and potential future therapeutic drugs against '
'COVID-19',
'volume': '11',
'author': 'Sha',
'year': '2023',
'journal-title': 'Front. Cell Dev. Biol.'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib229',
'doi-asserted-by': 'crossref',
'first-page': '472',
'DOI': '10.1109/TCBB.2019.2933825',
'article-title': 'An analytical review of computational drug repurposing',
'volume': '18',
'author': 'Sadeghi',
'year': '2021',
'journal-title': 'IEEE/ACM Trans Comput Biol Bioinform'},
{ 'key': '10.1016/j.mcp.2024.101973_bib230',
'series-title': 'Presented at the Proceedings of the 12th Hellenic Conference on '
'Artificial Intelligence',
'article-title': 'Mass enhanced node embeddings for drug repurposing',
'author': 'Chatzianastasis',
'year': '2022'},
{ 'issue': '6',
'key': '10.1016/j.mcp.2024.101973_bib231',
'doi-asserted-by': 'crossref',
'first-page': '831',
'DOI': '10.1007/s40258-023-00816-6',
'article-title': 'Drug repurposing of generic drugs: challenges and the potential role '
'for government',
'volume': '21',
'author': 'van der Pol',
'year': '2023',
'journal-title': 'Appl Health Econ Health Policy'},
{ 'issue': '5',
'key': '10.1016/j.mcp.2024.101973_bib232',
'doi-asserted-by': 'crossref',
'first-page': '730',
'DOI': '10.1002/cbic.202000047',
'article-title': 'Learning from the past: possible urgent prevention and treatment '
'options for severe acute respiratory infections caused by 2019-nCoV',
'volume': '21',
'author': 'Morse',
'year': '2020',
'journal-title': 'Chembiochem'},
{ 'issue': '11',
'key': '10.1016/j.mcp.2024.101973_bib233',
'doi-asserted-by': 'crossref',
'first-page': '907',
'DOI': '10.1002/cmdc.202000223',
'article-title': 'Drug development and medicinal chemistry efforts toward '
'SARS-coronavirus and covid-19 therapeutics',
'volume': '15',
'author': 'Ghosh',
'year': '2020',
'journal-title': 'ChemMedChem'},
{ 'key': '10.1016/j.mcp.2024.101973_bib234',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.antiviral.2022.105492',
'article-title': 'Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in '
'the rhesus macaque model',
'volume': '209',
'author': 'Johnson',
'year': '2023',
'journal-title': 'Antiviral Res'},
{ 'issue': '7850',
'key': '10.1016/j.mcp.2024.101973_bib235',
'doi-asserted-by': 'crossref',
'first-page': '451',
'DOI': '10.1038/s41586-021-03312-w',
'article-title': 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801',
'volume': '591',
'author': 'Wahl',
'year': '2021',
'journal-title': 'Nature'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib236',
'doi-asserted-by': 'crossref',
'DOI': '10.3390/microorganisms10020342',
'article-title': 'The nsp15 nuclease as a good target to combat SARS-CoV-2: mechanism of '
'action and its inactivation with FDA-approved drugs',
'volume': '10',
'author': 'Saramago',
'year': '2022',
'journal-title': 'Microorganisms'},
{ 'key': '10.1016/j.mcp.2024.101973_bib237',
'article-title': 'Overcoming nonstructural protein 15-nidoviral uridylate-specific '
'endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2',
'author': 'Sl',
'year': '2020',
'journal-title': 'Future Drug Discov'},
{ 'issue': '10',
'key': '10.1016/j.mcp.2024.101973_bib238',
'doi-asserted-by': 'crossref',
'first-page': '1757',
'DOI': '10.1039/D1MD00202C',
'article-title': 'A novel compound active against SARS-CoV-2 targeting uridylate-specific '
'endoribonuclease (NendoU/NSP15): in silico and in vitro investigations',
'volume': '12',
'author': 'Kumar',
'year': '2021',
'journal-title': 'RSC Med. Chem.'},
{ 'key': '10.1016/j.mcp.2024.101973_bib239',
'article-title': 'Biochemical characterization of emerging SARS-CoV-2 Nsp15 '
'endoribonuclease variants',
'volume': '35611336',
'author': 'Wilson',
'year': '2022',
'journal-title': 'bioRxiv'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib240',
'doi-asserted-by': 'crossref',
'first-page': '438',
'DOI': '10.1080/07391102.2020.1814870',
'article-title': 'Identification of promising antiviral drug candidates against '
'non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico '
'assisted drug-repurposing study',
'volume': '40',
'author': 'Khan',
'year': '2022',
'journal-title': 'J. Biomol. Struct. Dyn.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib241',
'doi-asserted-by': 'crossref',
'first-page': '99',
'DOI': '10.1016/j.medj.2020.07.002',
'article-title': 'Virus-host interactome and proteomic survey reveal potential virulence '
'factors influencing SARS-CoV-2 pathogenesis',
'volume': '2',
'author': 'Li',
'year': '2021',
'journal-title': 'Med'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib242',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.ppat.1008690',
'article-title': 'Inhibition of anti-viral stress granule formation by coronavirus '
'endoribonuclease nsp15 ensures efficient virus replication',
'volume': '17',
'author': 'Gao',
'year': '2021',
'journal-title': 'PLoS Pathog.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib243',
'doi-asserted-by': 'crossref',
'first-page': '1418',
'DOI': '10.1080/22221751.2020.1780953',
'article-title': 'SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon '
'antagonists',
'volume': '9',
'author': 'Yuen',
'year': '2020',
'journal-title': 'Emerg Microbes Infect'},
{ 'key': '10.1016/j.mcp.2024.101973_bib244',
'doi-asserted-by': 'crossref',
'DOI': '10.1097/MJT.0000000000001728',
'article-title': 'Delayed response to glucocorticoids in daptomycin lung',
'author': 'Nanah',
'year': '2024',
'journal-title': 'Am J Ther'},
{ 'issue': '2',
'key': '10.1016/j.mcp.2024.101973_bib245',
'doi-asserted-by': 'crossref',
'first-page': '280',
'DOI': '10.1080/20009666.2021.1883813',
'article-title': 'Eosinophilic pneumonia: a case of daptomycin induced lung injury',
'volume': '11',
'author': 'Raman',
'year': '2021',
'journal-title': 'J. Community Hosp. Intern. Med. Perspect.'},
{ 'issue': '1',
'key': '10.1016/j.mcp.2024.101973_bib246',
'doi-asserted-by': 'crossref',
'first-page': '218',
'DOI': '10.1007/s13311-019-00775-8',
'article-title': 'Calming down mast cells with ketotifen: a potential strategy for '
'multiple sclerosis therapy?',
'volume': '17',
'author': 'Pinke',
'year': '2020',
'journal-title': 'Neurotherapeutics'},
{ 'key': '10.1016/j.mcp.2024.101973_bib247',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.lfs.2023.121537',
'article-title': 'Ketotifen is a microglial stabilizer by inhibiting secretory vesicle '
'acidification',
'volume': '319',
'author': 'Ramirez-Ponce',
'year': '2023',
'journal-title': 'Life Sci.'}],
'container-title': 'Molecular and Cellular Probes',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0890850824000252?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0890850824000252?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2024, 7, 26]],
'date-time': '2024-07-26T04:50:16Z',
'timestamp': 1721969416000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0890850824000252'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 10]]},
'references-count': 246,
'alternative-id': ['S0890850824000252'],
'URL': 'http://dx.doi.org/10.1016/j.mcp.2024.101973',
'relation': {},
'ISSN': ['0890-8508'],
'subject': [],
'container-title-short': 'Molecular and Cellular Probes',
'published': {'date-parts': [[2024, 10]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'SARS-CoV-2 replication and drug discovery',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'Molecular and Cellular Probes', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.mcp.2024.101973',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2024 The Authors. Published by Elsevier Ltd.',
'name': 'copyright',
'label': 'Copyright'}],
'article-number': '101973'}
